Scott E.EggenerScott E. Eggener41.78927490000000-87.601250000000001156Eggener, Scott E.Dr. Eggener’s research and clinical interests focus on improving the management and outcomes for patients with localized prostate cancer with specific emphasis on active surveillance, focal therapy and optimizing surgical outcomes. He has published extensively on prostate cancer with 75 peer-reviewed publications and multiple on PSA screening, surgery, prostate imaging, active surveillance or focal therapy for prostate cancer. He is on the editorial board of four journals, including Prostate Cancer and Prostatic Diseases.Professorplugins:FeaturedVideosFeatured Videosplugins:TwitterTwitterprns:coAuthorOfcoauthor ofprns:emailEncryptedemail addressFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:pluginSearchableDataProfilesRNS Plugin Searchable Dataprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:trainingAtOrganizationeducational organizationprns:trainingLocationtraining locationprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipvivo:degreeEarneddegree earnedDepartmentvivo:educationalTrainingeducation and trainingEducational Trainingvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkAnchorTextlink anchor textvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:overviewoverviewvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titleURLLinkvivo:webpagewebpagerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonAuthorship 1003823Authorship 1015584Authorship 101626527948049Jang TL, Pettus JA, Huang WC, Eggener SE, O'Brien MF, Karellas ME, Kagiwada MA, Russo PJournal of clinical oncology : official journal of the American Society of Clinical OncologySurvival rates after resection for localized kidney cancer: 1989 - 2004. J Clin Oncol. 2008 May 20; 26(15_suppl):5115.J Clin Oncol2008-05-20T00:00:002008Survival rates after resection for localized kidney cancer: 1989 - 2004.27670878Verma S, Rosenkrantz AB, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K, Haider MA, Margolis DJ, Marks LS, Pinto P, Sonn GA, Taneja SSAbdominal radiology (New York)Commentary regarding a recent collaborative consensus statement addressing prostate MRI and MRI-targeted biopsy in patients with a prior negative prostate biopsy. Abdom Radiol (NY). 2017 Feb; 42(2):346-349.Abdom Radiol (NY)2017-02-01T00:00:002017Commentary regarding a recent collaborative consensus statement addressing prostate MRI and MRI-targeted biopsy in patients with a prior negative prostate biopsy.27147477Browne JA, Yang R, Eggener SE, Leir SH, Harris AMolecular and cellular endocrinologyErratum to "HNF1 regulates critical processes in the human epididymis epithelium" [Mol. Cell. Endocrinol. 425 (2016) 94-102]. Mol Cell Endocrinol. 2016 Jun 15; 428:174.Mol Cell Endocrinol2016-06-15T00:00:002016Erratum to "HNF1 regulates critical processes in the human epididymis epithelium" [Mol. Cell. Endocrinol. 425 (2016) 94-102].Authorship 101817528302349Tallman JE, Packiam VT, Wroblewski KE, Paner GP, Eggener SEUrologic oncologyInfluence of pathologist experience on positive surgical margins following radical prostatectomy. Urol Oncol. 2017 07; 35(7):461.e1-461.e6.Urol Oncol2017-03-13T00:00:002017Influence of pathologist experience on positive surgical margins following radical prostatectomy.Authorship 102019328318726Moschini M, Carroll PR, Eggener SE, Epstein JI, Graefen M, Montironi R, Parker CEuropean urologyLow-risk Prostate Cancer: Identification, Management, and Outcomes. Eur Urol. 2017 08; 72(2):238-249.Eur Urol2017-03-18T00:00:002017Low-risk Prostate Cancer: Identification, Management, and Outcomes.Authorship 103563728436357Ericson KJ, Wenger HC, Rosen AM, Kiriluk KJ, Gerber GS, Paner GP, Eggener SEThe Canadian journal of urologyProstate cancer detection following diagnosis of atypical small acinar proliferation. Can J Urol. 2017 Apr; 24(2):8714-8720.Can J Urol2017-04-01T00:00:002017Prostate cancer detection following diagnosis of atypical small acinar proliferation.Authorship 104283928483574Fulgham PF, Rukstalis DB, Turkbey IB, Rubenstein JN, Taneja S, Carroll PR, Pinto PA, Bjurlin MA, Eggener SThe Journal of urologyAUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer. J Urol. 2017 10; 198(4):832-838.J Urol2017-05-05T00:00:002017AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer.Authorship 104447528551443Tallman JE, Pearce SM, Kuchta K, Helfand BT, Eggener SEThe Journal of urologyImpact of Perioperative Infection on Cancer Specific Survival after Nephrectomy for Renal Cell Carcinoma. J Urol. 2017 11; 198(5):1027-1032.J Urol2017-05-25T00:00:002017Impact of Perioperative Infection on Cancer Specific Survival after Nephrectomy for Renal Cell Carcinoma.Authorship 105662628631720Weiner AB, Matulewicz RS, Schaeffer EM, Liauw SL, Feinglass JM, Eggener SEProstate cancer and prostatic diseasesContemporary management of men with high-risk localized prostate cancer in the United States. Prostate Cancer Prostatic Dis. 2017 09; 20(3):283-288.Prostate Cancer Prostatic Dis2017-06-20T00:00:002017Contemporary management of men with high-risk localized prostate cancer in the United States.Radiation and Cellular Oncology29770853Tretiakova M, Mehta V, Kocherginsky M, Minor A, Shen SS, Sirintrapun SJ, Yao JL, Alvarado-Cabrero I, Antic T, Eggener SE, Picken MM, Paner GPVirchows Archiv : an international journal of pathologyPredominantly cystic clear cell renal cell carcinoma and multilocular cystic renal neoplasm of low malignant potential form a low-grade spectrum. Virchows Arch. 2018 Jul; 473(1):85-93.Virchows Arch2018-05-17T00:00:002018Predominantly cystic clear cell renal cell carcinoma and multilocular cystic renal neoplasm of low malignant potential form a low-grade spectrum.29702525He D, Chatterjee A, Fan X, Wang S, Eggener S, Yousuf A, Antic T, Oto A, Karczmar GSInvestigative radiologyFeasibility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using Low-Dose Gadolinium: Comparative Performance With Standard Dose in Prostate Cancer Diagnosis. Invest Radiol. 2018 10; 53(10):609-615.Invest Radiol2018-10-01T00:00:002018Feasibility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using Low-Dose Gadolinium: Comparative Performance With Standard Dose in Prostate Cancer Diagnosis.Authorship 10962110Authorship 109596530447155Knull E, Oto A, Eggener S, Tessier D, Guneyli S, Chatterjee A, Fenster AMedical physicsEvaluation of tumor coverage after MR-guided prostate focal laser ablation therapy. Med Phys. 2019 Feb; 46(2):800-810.Med Phys2018-12-07T00:00:002018Evaluation of tumor coverage after MR-guided prostate focal laser ablation therapy.29995499Westin C, Chatterjee A, Ku E, Yousuf A, Wang S, Thomas S, Fan X, Eggener S, Karczmar G, Oto AAJR. American journal of roentgenologyMRI Findings After MRI-Guided Focal Laser Ablation of Prostate Cancer. AJR Am J Roentgenol. 2018 09; 211(3):595-604.AJR Am J Roentgenol2018-07-11T00:00:002018MRI Findings After MRI-Guided Focal Laser Ablation of Prostate Cancer.Authorship 1098898Authorship 1098853Authorship 1112772Authorship 1114751Authorship 1116312Authorship 1124673Authorship 1122011Authorship 1122463Authorship 11484613Authorship 1160602Authorship 11225410Authorship 1168323Authorship 1129131Authorship 1132224Authorship 1178943Authorship 1179102Authorship 1136682Authorship 1184203Authorship 1190893Authorship 1194939Authorship 1190683Authorship 1208916Authorship 1211993Authorship 1230542Authorship 12305517Authorship 1233947Authorship 1233994Authorship 12475713Authorship 1251474Authorship 1183126Authorship 1186693Authorship 121067329288121Bernstein AN, Shoag JE, Golan R, Halpern JA, Schaeffer EM, Hsu WC, Nguyen PL, Sedrakyan A, Chen RC, Eggener SE, Hu JCThe Journal of urologyContemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases. J Urol. 2018 06; 199(6):1510-1517.J Urol2017-12-26T00:00:002017Contemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases.28801218Chow AK, Sherer BA, Yura E, Kielb S, Kocjancic E, Eggener S, Turk T, Park S, Psutka S, Abern M, Latchamsetty KC, Coogan CLUrologyUrology Residents' Experience and Attitude Toward Surgical Simulation: Presenting our 4-Year Experience With a Multi-institutional, Multi-modality Simulation Model. Urology. 2017 Nov; 109:32-37.Urology2017-08-08T00:00:002017Urology Residents' Experience and Attitude Toward Surgical Simulation: Presenting our 4-Year Experience With a Multi-institutional, Multi-modality Simulation Model.28808871Smith ZL, Eggener SE, Murphy ABCurrent urology reportsAfrican-American Prostate Cancer Disparities. Curr Urol Rep. 2017 Aug 14; 18(10):81.Curr Urol Rep2017-08-14T00:00:002017African-American Prostate Cancer Disparities.29552975Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM, PRECISION Study Group CollaboratorsThe New England journal of medicineMRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018 May 10; 378(19):1767-1777.N Engl J Med2018-03-18T00:00:002018MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.30016502Yang R, Browne JA, Eggener SE, Leir SH, Harris AMolecular human reproductionA novel transcriptional network for the androgen receptor in human epididymis epithelial cells. Mol Hum Reprod. 2018 09 01; 24(9):433-443.Mol Hum Reprod2018-09-01T00:00:002018A novel transcriptional network for the androgen receptor in human epididymis epithelial cells.29709434Packiam VT, Nottingham CU, Cohen AJ, Eggener SE, Gerber GSUrologyNo Effect of Music on Anxiety and Pain During Transrectal Prostate Biopsies: A Randomized Trial. Urology. 2018 Jul; 117:31-35.Urology2018-04-27T00:00:002018No Effect of Music on Anxiety and Pain During Transrectal Prostate Biopsies: A Randomized Trial.29943219Lodeizen O, de Bruin M, Eggener S, Crouzet S, Ghai S, Varkarakis I, Katz A, Dominguez-Escrig JL, Pahernik S, de Reijke T, de la Rosette JWorld journal of urologyAblation energies for focal treatment of prostate cancer. World J Urol. 2019 Mar; 37(3):409-418.World J Urol2018-06-25T00:00:002018Ablation energies for focal treatment of prostate cancer.29979235Werntz RP, Pearce SM, Eggener SECurrent opinion in urologyIndications, evolving technique, and early outcomes with robotic retroperitoneal lymph node dissection. Curr Opin Urol. 2018 09; 28(5):461-468.Curr Opin Urol2018-09-01T00:00:002018Indications, evolving technique, and early outcomes with robotic retroperitoneal lymph node dissection.30224197Weiner AB, Schaeffer EM, Eggener SEEuropean urology"Real-world" Practice Makes Perfect: Ensuring the Active Component of Active Surveillance for Prostate Cancer. Eur Urol. 2018 12; 74(6):708-709.Eur Urol2018-09-14T00:00:002018"Real-world" Practice Makes Perfect: Ensuring the Active Component of Active Surveillance for Prostate Cancer.28814450Smith ZL, Eggener SEEvidence-based medicineIn localised prostate cancer, radical prostatectomy was associated with more sexual dysfunction and urinary incontinence than radiation or active surveillance. Evid Based Med. 2017 10; 22(5):192.Evid Based Med2017-08-16T00:00:002017In localised prostate cancer, radical prostatectomy was associated with more sexual dysfunction and urinary incontinence than radiation or active surveillance.29224914Eggener SEuropean urologyNodal Metastases at Radical Prostatectomy: More Aggressive Disease Warrants Consideration of Multimodal Treatment. Eur Urol. 2018 06; 73(6):897-898.Eur Urol2017-12-08T00:00:002017Nodal Metastases at Radical Prostatectomy: More Aggressive Disease Warrants Consideration of Multimodal Treatment.29232270Werntz RP, Eggener SECurrent opinion in urologyNovel focal therapy treatment options for prostate cancer. Curr Opin Urol. 2018 03; 28(2):178-183.Curr Opin Urol2018-03-01T00:00:002018Novel focal therapy treatment options for prostate cancer.28723430Eggener SEuropean urology focusKnown Knowns, Known Unknowns, and Unknown Unknowns of High-intensity Focused Ultrasound for Prostate Cancer. Eur Urol Focus. 2015 Sep; 1(2):171-172.Eur Urol Focus2015-07-27T00:00:002015Known Knowns, Known Unknowns, and Unknown Unknowns of High-intensity Focused Ultrasound for Prostate Cancer.29339104Browne JA, Leir SH, Eggener SE, Harris AMolecular and cellular endocrinologyRegion-specific innate antiviral responses of the human epididymis. Mol Cell Endocrinol. 2018 09 15; 473:72-78.Mol Cell Endocrinol2018-01-13T00:00:002018Region-specific innate antiviral responses of the human epididymis.29406056Smith ZL, Werntz RP, Eggener SEThe Medical clinics of North AmericaTesticular Cancer: Epidemiology, Diagnosis, and Management. Med Clin North Am. 2018 Mar; 102(2):251-264.Med Clin North Am2017-12-21T00:00:002017Testicular Cancer: Epidemiology, Diagnosis, and Management.30288142Pieczonka CM, Twardowski P, Renzulli J, Hafron J, Boldt-Houle DM, Atkinson S, Eggener SReviews in urologyEffectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients. Rev Urol. 2018; 20(2):63-68.Rev Urol2018-01-01T00:00:002018Effectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients.30291653Wang S, Fan X, Yousuf A, Eggener SE, Karczmar G, Oto AJournal of magnetic resonance imaging : JMRIEvaluation of Focal Laser Ablation of Prostate Cancer Using High Spectral and Spatial Resolution Imaging: A Pilot Study. J Magn Reson Imaging. 2019 05; 49(5):1374-1380.J Magn Reson Imaging2018-10-06T00:00:002018Evaluation of Focal Laser Ablation of Prostate Cancer Using High Spectral and Spatial Resolution Imaging: A Pilot Study.29107276Rodriguez JF, Liauw SL, Eggener SEThe Urologic clinics of North AmericaManaging Cancer Relapse After Radical Prostatectomy: Adjuvant Versus Salvage Radiation Therapy. Urol Clin North Am. 2017 Nov; 44(4):597-609.Urol Clin North Am2017-11-01T00:00:002017Managing Cancer Relapse After Radical Prostatectomy: Adjuvant Versus Salvage Radiation Therapy.29279663Wenger H, Razmaria A, Eggener S, Raman JDJSLS : Journal of the Society of Laparoendoscopic SurgeonsNerve Bundle Hydrodissection and Sexual Function after Robot Prostatectomy. JSLS. 2017 Oct-Dec; 21(4).JSLS2017-10-01T00:00:002017Nerve Bundle Hydrodissection and Sexual Function after Robot Prostatectomy.29127213Packiam VT, Eggener SEEvidence-based medicineMinimal difference in survival between radical prostatectomy and observation in men with modest life expectancy. Evid Based Med. 2017 12; 22(6):222.Evid Based Med2017-11-10T00:00:002017Minimal difference in survival between radical prostatectomy and observation in men with modest life expectancy.29765545Dinizo M, Shih W, Kwon YS, Eun D, Reese A, Giusto L, Trabulsi EJ, Yuh B, Ruel N, Marchalik D, Hwang J, Kundu SD, Eggener S, Kim IYOncotargetMulti-institution analysis of racial disparity among African-American men eligible for prostate cancer active surveillance. Oncotarget. 2018 Apr 20; 9(30):21359-21365.Oncotarget2018-04-20T00:00:002018Multi-institution analysis of racial disparity among African-American men eligible for prostate cancer active surveillance.29174615Eggener SEuropean urology focusCan Focal Treatment Replace Radical Treatment in Prostate Cancer? For Focal Therapy. Eur Urol Focus. 2017 12; 3(6):522-523.Eur Urol Focus2017-11-23T00:00:002017Can Focal Treatment Replace Radical Treatment in Prostate Cancer? For Focal Therapy.29420975Rodriguez JF, Eggener SERadiologic clinics of North AmericaProstate Cancer and the Evolving Role of Biomarkers in Screening and Diagnosis. Radiol Clin North Am. 2018 Mar; 56(2):187-196.Radiol Clin North Am2017-11-26T00:00:002017Prostate Cancer and the Evolving Role of Biomarkers in Screening and Diagnosis.29125150Weiner AB, Matulewicz RS, Schaeffer EM, Liauw SL, Feinglass JM, Eggener SEProstate cancer and prostatic diseasesContemporary management of men with high-risk localized prostate cancer in the United States. Prostate Cancer Prostatic Dis. 2017 12; 20(4):442.Prostate Cancer Prostatic Dis2017-12-01T00:00:002017Contemporary management of men with high-risk localized prostate cancer in the United States.30058558Browne JA, Leir SH, Eggener SE, Harris AAsian journal of andrologyRegion-specific microRNA signatures in the human epididymis. Asian J Androl. 2018 Nov-Dec; 20(6):539-544.Asian J Androl2018-11-01T00:00:002018Region-specific microRNA signatures in the human epididymis.29236593Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LGJournal of clinical oncology : official journal of the American Society of Clinical OncologyRole of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018 02 01; 36(4):414-424.J Clin Oncol2017-12-13T00:00:002017Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.28753804Kane CJ, Eggener SE, Shindel AW, Andriole GLEuropean urology focusVariability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2-3) and Implications for Risk Stratification: A Systematic Review. Eur Urol Focus. 2017 10; 3(4-5):487-497.Eur Urol Focus2017-03-11T00:00:002017Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2-3) and Implications for Risk Stratification: A Systematic Review.29732276Dall'Era MA, Davies BJ, Eggener STranslational andrology and urologyActive surveillance for prostate cancer. Transl Androl Urol. 2018 Apr; 7(2):195-196.Transl Androl Urol2018-04-01T00:00:002018Active surveillance for prostate cancer.30170087Riedinger CB, Labbate C, Werntz RP, Eggener SEUrologyLate Relapse of Nonseminomatous Germ Cell Tumor 24 Years Later. Urology. 2018 Dec; 122:16-18.Urology2018-08-28T00:00:002018Late Relapse of Nonseminomatous Germ Cell Tumor 24 Years Later.30179635Johnson SC, Smith ZL, Nottingham C, Schwen ZR, Thomas S, Fishman EK, Lee NJ, Pierorazio PM, Eggener SEUrologyClinical and Radiographic Predictors of Great Vessel Resection or Reconstruction During Retroperitoneal Lymph Node Dissection for Testicular Cancer. Urology. 2019 01; 123:186-190.Urology2018-09-01T00:00:002018Clinical and Radiographic Predictors of Great Vessel Resection or Reconstruction During Retroperitoneal Lymph Node Dissection for Testicular Cancer.Authorship 125524530540213Sun C, Chatterjee A, Yousuf A, Antic T, Eggener S, Karczmar GS, Oto AAJR. American journal of roentgenologyComparison of T2-Weighted Imaging, DWI, and Dynamic Contrast-Enhanced MRI for Calculation of Prostate Cancer Index Lesion Volume: Correlation With Whole-Mount Pathology. AJR Am J Roentgenol. 2019 02; 212(2):351-356.AJR Am J Roentgenol2018-12-12T00:00:002018Comparison of T2-Weighted Imaging, DWI, and Dynamic Contrast-Enhanced MRI for Calculation of Prostate Cancer Index Lesion Volume: Correlation With Whole-Mount Pathology.Authorship 125770230578120Pierorazio P, Eggener SEuropean urologyObscenity, Michael Jordan, and Measuring Outcomes: Explaining and Improving the Quality of Kidney Cancer Care. Eur Urol. 2019 04; 75(4):635-636.Eur Urol2018-12-19T00:00:002018Obscenity, Michael Jordan, and Measuring Outcomes: Explaining and Improving the Quality of Kidney Cancer Care.Authorship 1265121Authorship 126478130611659Eggener S, Karsh LI, Richardson T, Shindel AW, Lu R, Rosenberg S, Goldfischer E, Korman H, Bennett J, Newmark J, Denes BSUrologyA 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility. Urology. 2019 04; 126:76-82.Urology2019-01-03T00:00:002019A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility.30634353Eggener SThe Journal of urologyEditorial Comment. J Urol. 2019 02; 201(2):266-267.J Urol2019-02-01T00:00:002019Editorial Comment.Authorship 1269521030671638van Luijtelaar A, Greenwood BM, Ahmed HU, Barqawi AB, Barret E, Bomers JGR, Brausi MA, Choyke PL, Cooperberg MR, Eggener S, Feller JF, Frauscher F, George AK, Hindley RG, Jenniskens SFM, Klotz L, Kovacs G, Lindner U, Loeb S, Margolis DJ, Marks LS, May S, Mcclure TD, Montironi R, Nour SG, Oto A, Polascik TJ, Rastinehad AR, De Reyke TM, Reijnen JS, de la Rosette JJMCH, Sedelaar JPM, Sperling DS, Walser EM, Ward JF, Villers A, Ghai S, Fütterer JJWorld journal of urologyFocal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project. World J Urol. 2019 Oct; 37(10):2147-2153.World J Urol2019-01-22T00:00:002019Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project.Authorship 1280511Authorship 128258630787672Eggener SReviews in urologyFocal Therapy for Localized Prostate Cancer. Rev Urol. 2018; 20(4):143-144.Rev Urol2018-01-01T00:00:002018Focal Therapy for Localized Prostate Cancer.30857555Labbate C, Hatogai K, Werntz R, Stadler WM, Steinberg GD, Eggener S, Sweis RFJournal for immunotherapy of cancerComplete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy. J Immunother Cancer. 2019 03 11; 7(1):66.J Immunother Cancer2019-03-11T00:00:002019Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy.Authorship 12877313Authorship 128901230968729Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, Drake CG, Heng DY, Lara PN, Choueiri TK, Maskens D, Singer EA, Eggener SE, Svatek RS, Stadler WM, Cole S, Signoretti S, Gupta RT, Michaelson MD, McDermott DF, Cella D, Wagner LI, Haas NB, Carducci MA, Harshman LC, Allaf MEFuture oncology (London, England)The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol. 2019 May; 15(15):1683-1695.Future Oncol2019-04-10T00:00:002019The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?30962042Werntz RP, Eggener SEEuropean urologyRe: Use of Active Surveillance or Watchful Waiting for Low-risk Prostate Cancer and Management Trends Across Risk Groups in the United States 2010-2015. Eur Urol. 2019 08; 76(2):252.Eur Urol2019-04-05T00:00:002019Re: Use of Active Surveillance or Watchful Waiting for Low-risk Prostate Cancer and Management Trends Across Risk Groups in the United States 2010-2015.Authorship 146661Authorship 129212431009740Osterberg EC, Golan S, Pes MPL, Eggener SE, Petrut B, Singh SK, Sountoulides P, Türkeri LN, Wolf JSUrologyInternational and Multi-institutional Assessment of Factors Associated With Performance and Quality of Lymph Node Dissection During Radical Nephrectomy. Urology. 2019 Jul; 129:132-138.Urology2019-04-19T00:00:002019International and Multi-institutional Assessment of Factors Associated With Performance and Quality of Lymph Node Dissection During Radical Nephrectomy.31039019Chatterjee A, He D, Fan X, Antic T, Jiang Y, Eggener S, Karczmar GS, Oto AAJR. American journal of roentgenologyDiagnosis of Prostate Cancer by Use of MRI-Derived Quantitative Risk Maps: A Feasibility Study. AJR Am J Roentgenol. 2019 08; 213(2):W66-W75.AJR Am J Roentgenol2019-04-30T00:00:002019Diagnosis of Prostate Cancer by Use of MRI-Derived Quantitative Risk Maps: A Feasibility Study.Authorship 1293714Authorship 129291631054211Bhanvadia RR, Rodriguez J, Bagrodia A, Eggener SEBJU internationalLymph node count impacts survival following post-chemotherapy retroperitoneal lymphadenectomy for non-seminomatous testicular cancer: a population-based analysis. BJU Int. 2019 11; 124(5):792-800.BJU Int2019-06-02T00:00:002019Lymph node count impacts survival following post-chemotherapy retroperitoneal lymphadenectomy for non-seminomatous testicular cancer: a population-based analysis.Authorship 1294641Authorship 1294657Authorship 129416231067164Eggener SThe Journal of urologyEditorial Comment. J Urol. 2019 08; 202(2):263.J Urol2019-07-08T00:00:002019Editorial Comment.31059667Stephenson A, Eggener SE, Bass EB, Chelnick DM, Daneshmand S, Feldman D, Gilligan T, Karam JA, Leibovich B, Liauw SL, Masterson TA, Meeks JJ, Pierorazio PM, Sharma R, Sheinfeld JThe Journal of urologyDiagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. J Urol. 2019 08; 202(2):272-281.J Urol2019-07-08T00:00:002019Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline.31067347Pinsky PF, Black A, Daugherty SE, Hoover R, Parnes H, Smith ZL, Eggener S, Andriole GL, Berndt SICancerMetastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer. 2019 09 01; 125(17):2965-2974.Cancer2019-05-08T00:00:002019Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.Authorship 194381Authorship 129764331113644Akthar AS, Liao C, Eggener SE, Liauw SLEuropean urologyPatient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy. Eur Urol. 2019 11; 76(5):686-692.Eur Urol2019-05-19T00:00:002019Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy.Authorship 1298376Authorship 129808631144591Gross MD, Sedrakyan A, Bianco FJ, Carroll PR, Daskivich TJ, Eggener SE, Ehdaie B, Fisher B, Gorin MA, Hunt B, Jiang H, Klein EA, Marinac-Dabic D, Montgomery JS, Polascik TJ, Priester AM, Rastinehad AR, Viviano CJ, Wysock JS, Hu JCThe Journal of urologySPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer. J Urol. 2019 11; 202(5):952-958.J Urol2019-10-09T00:00:002019SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer.31128968Cooperberg MR, Carroll PR, Dall'Era MA, Davies BJ, Davis JW, Eggener SE, Feng FY, Lin DW, Morgan TM, Morgans AK, Spratt DE, Taneja SS, Penson DFEuropean urologyThe State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. Eur Urol. 2019 Sep; 76(3):268-272.Eur Urol2019-05-23T00:00:002019The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement.Authorship 202623Authorship 129895631158094Barashi NS, Pearce SM, Cohen AJ, Pariser JJ, Packiam VT, Eggener SEEuropean urology oncologyIncidence, Risk Factors, and Outcomes for Rectal Injury During Radical Prostatectomy: A Population-based Study. Eur Urol Oncol. 2018 12; 1(6):501-506.Eur Urol Oncol2018-06-29T00:00:002018Incidence, Risk Factors, and Outcomes for Rectal Injury During Radical Prostatectomy: A Population-based Study.31200839Truong M, Baack Kukreja JE, Rais-Bahrami S, Barashi NS, Wang B, Nuffer Z, Park JH, Lam K, Frye TP, Nix JW, Thomas JV, Feng C, Chapin BF, Davis JW, Hollenberg G, Oto A, Eggener SE, Joseph JV, Weinberg E, Messing EMEuropean urology oncologyMulti-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance Imaging. Eur Urol Oncol. 2019 05; 2(3):257-264.Eur Urol Oncol2019-01-04T00:00:002019Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance Imaging.Authorship 13008417Authorship 200985Authorship 236481Authorship 205872Authorship 215462Authorship 251952Authorship 213912Authorship 230801Authorship 130530831272940Ghandour R, Ashbrook C, Freifeld Y, Singla N, El-Asmar JM, Lotan Y, Margulis V, Eggener S, Woldu S, Bagrodia AEuropean urology oncologyNationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle. Eur Urol Oncol. 2020 04; 3(2):198-206.Eur Urol Oncol2019-07-01T00:00:002019Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle.Memorial Sloan-Kettering Cancer CenterNew YorkMemorial Sloan-Kettering Cancer Center, Urologic oncology fellowshipNorthwestern Memorial HospitalChicagoNorthwestern Memorial Hospital, General and urologic surgery internship and residencyStandford University School of MedicineCaliforniaStandford University School of Medicine, MDAuthorship 239621Authorship 219273Authorship 222133Authorship 264831Authorship 245121Authorship 274272Authorship 274451Authorship 259913Authorship 1321106Authorship 132060131364932Gross MD, Sedrakyan A, Bianco FJ, Carroll PR, Daskivich TJ, Eggener SE, Ehdaie B, Fisher B, Gorin MA, Hunt B, Jiang H, Klein EA, Marinac-Dabic D, Montgomery JS, Polascik TJ, Priester AM, Rastinehad AR, Viviano CJ, Wysock JS, Hu JCThe Journal of urologyReply by Authors. J Urol. 2019 11; 202(5):958.J Urol2019-10-09T00:00:002019Reply by Authors.31364943Eggener SThe Journal of urologyEditorial Comment. J Urol. 2019 11; 202(5):942-943.J Urol2019-10-09T00:00:002019Editorial Comment.Authorship 266821Authorship 244381Authorship 299241Authorship 285961Authorship 268701Authorship 1328157Authorship 1328421131502940Weinstock C, Suzman D, Kluetz P, Baxley J, Viviano C, Ibrahim A, Jarow J, Sridhara R, Liu K, Carroll P, Eggener S, Hu JC, Hussain M, King M, Klein E, Kungel T, Makarov D, Pinto PA, Rini B, Roach M, Sandler H, Schlegel PN, Song D, Goldberg K, Pazdur R, Beaver JAThe Journal of urologyDevelopment of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop. J Urol. 2020 01; 203(1):115-119.J Urol2019-09-10T00:00:002019Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop.31501508Baack Kukreja J, Bathala TK, Reichard CA, Troncoso P, Delacroix S, Davies B, Eggener S, Smaldone M, Minhaj Siddiqui M, Tollefson M, Chapin BFProstate cancer and prostatic diseasesImpact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2020 03; 23(1):172-178.Prostate Cancer Prostatic Dis2019-09-09T00:00:002019Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer.Authorship 314801Authorship 299252Authorship 303672Authorship 303681Authorship 332461Authorship 332561Authorship 310831Authorship 274103Authorship 344951Authorship 133121231543365Porter J, Eggener S, Castle E, Pierorazio PEuropean urologyRecurrence After Robotic Retroperitoneal Lymph Node Dissection Raises More Questions than Answers. Eur Urol. 2019 11; 76(5):610-611.Eur Urol2019-09-19T00:00:002019Recurrence After Robotic Retroperitoneal Lymph Node Dissection Raises More Questions than Answers.Authorship 3527019Authorship 325275Authorship 308882Authorship 371792Authorship 283395Authorship 3868520Authorship 323102Authorship 355971Authorship 133752331642740Bjurlin MA, Carroll PR, Eggener S, Fulgham PF, Margolis DJ, Pinto PA, Rosenkrantz AB, Rubenstein JN, Rukstalis DB, Taneja SS, Turkbey BThe Journal of urologyUpdate of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer. J Urol. 2020 Apr; 203(4):706-712.J Urol2019-10-23T00:00:002019Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer.D009373Disorders22470.941497Neoplasms, Germ Cell and EmbryonalAuthorship 369321Authorship 372552Authorship 299531Authorship 304892Authorship 377712Authorship 309582Authorship 378592Authorship 381469Authorship 383887Authorship 1342641031728517Liauw SL, Ham SA, Das LC, Rudra S, Packiam VT, Koshy M, Weichselbaum RR, Becker YT, Bodzin AS, Eggener SEJournal of the National Cancer InstituteProstate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis. J Natl Cancer Inst. 2020 08 01; 112(8):847-854.J Natl Cancer Inst2020-08-01T00:00:002020Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis.Authorship 374081Authorship 134422131742661Eggener SECancerRecognizing and minimizing bias: Helping patients make their best choice for prostate cancer management through multidisciplinary clinics. Cancer. 2020 02 01; 126(3):470-472.Cancer2019-11-19T00:00:002019Recognizing and minimizing bias: Helping patients make their best choice for prostate cancer management through multidisciplinary clinics.Authorship 415713Authorship 309263Authorship 395023Authorship 397384Authorship 323401D011471Disorders23517080.438658Prostatic NeoplasmsAuthorship 331413Authorship 134761131829902Eggener SE, Rumble RB, Armstrong AJ, Morgan TM, Crispino T, Cornford P, van der Kwast T, Grignon DJ, Rai AJ, Agarwal N, Klein EA, Den RB, Beltran HJournal of clinical oncology : official journal of the American Society of Clinical OncologyMolecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. J Clin Oncol. 2020 05 01; 38(13):1474-1494.J Clin Oncol2019-12-12T00:00:002019Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline.Authorship 450434Authorship 410301Authorship 329016Authorship 440651Authorship 366911Authorship 348474Authorship 372902Authorship 468897Authorship 4713411Authorship 4393710Authorship 480656Authorship 364383Authorship 345841Authorship 386657Authorship 1357542Authorship 135709132048932Eggener SE, Rumble RB, Beltran HJCO oncology practiceMolecular Biomarkers in Localized Prostate Cancer: ASCO Guideline Summary. JCO Oncol Pract. 2020 06; 16(6):340-343.JCO Oncol Pract2020-01-28T00:00:002020Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline Summary.32055483Werntz RP, Eggener SETranslational andrology and urologyDefining risk of micrometastatic disease and tumor recurrence in patients with stage I testicular germ cell tumors. Transl Androl Urol. 2020 Jan; 9(Suppl 1):S31-S35.Transl Androl Urol2020-01-01T00:00:002020Defining risk of micrometastatic disease and tumor recurrence in patients with stage I testicular germ cell tumors.Authorship 361104Authorship 467782Authorship 355691Authorship 478083Authorship 362341Authorship 363673Authorship 378421Authorship 398782Authorship 399761Authorship 382121Authorship 382131Authorship 4080310Authorship 408063Authorship 399396Authorship 137046532305267Labbate CV, Werntz RP, Galansky LB, Packiam VT, Eggener SEUrologic oncologyNational management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy. Urol Oncol. 2020 08; 38(8):687.e13-687.e18.Urol Oncol2020-04-15T00:00:002020National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy.Authorship 4251711Authorship 457284Authorship 461466Authorship 97773Authorship 468064Authorship 413719Authorship 425305Authorship 137693132432506Eggener SThe Journal of urologyEditorial Comment. J Urol. 2020 08; 204(2):287.J Urol2020-05-20T00:00:002020Editorial Comment.Authorship 436097Authorship 444865Authorship 1382175332516092Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O'Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LGJournal of clinical oncology : official journal of the American Society of Clinical OncologyImplementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020 08 20; 38(24):2798-2811.J Clin Oncol2020-06-09T00:00:002020Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.Authorship 484274Authorship 138802232593531Modi PK, Eggener SEEuropean urologyProstate-specific Antigen to Predict Early Success of Focal Therapy: Focusing on Appropriate Endpoints. Eur Urol. 2020 08; 78(2):161-162.Eur Urol2020-06-25T00:00:002020Prostate-specific Antigen to Predict Early Success of Focal Therapy: Focusing on Appropriate Endpoints.Authorship 467172Authorship 469022Authorship 478662D013736Disorders451040.896268Testicular NeoplasmsAuthorship 139878532785769Sun C, Wang S, Chatterjee A, Medved M, Eggener S, Karczmar GS, Oto AEuropean radiologyT2*-weighted MRI as a non-contrast-enhanced method for assessment of focal laser ablation zone extent in prostate cancer thermotherapy. Eur Radiol. 2021 Jan; 31(1):325-332.Eur Radiol2020-08-12T00:00:002020T2*-weighted MRI as a non-contrast-enhanced method for assessment of focal laser ablation zone extent in prostate cancer thermotherapy.Authorship 333192Authorship 350385Authorship 363535Authorship 371621Authorship 386583Authorship 422481Authorship 4305312Authorship 436491Authorship 481614Authorship 482785Authorship 487331Authorship 14110525Authorship 1410772532976703Al-Adra DP, Hammel L, Roberts J, Woodle ES, Levine D, Mandelbrot D, Verna E, Locke J, D'Cunha J, Farr M, Sawinski D, Agarwal PK, Plichta J, Pruthi S, Farr D, Carvajal R, Walker J, Zwald F, Habermann T, Gertz M, Bierman P, Dizon DS, Langstraat C, Al-Qaoud T, Eggener S, Richgels JP, Chang GJ, Geltzeiler C, Sapisochin G, Ricciardi R, Krupnick AS, Kennedy C, Mohindra N, Foley DP, Watt KDAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant SurgeonsPreexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. Am J Transplant. 2021 02; 21(2):475-483.Am J Transplant2020-10-10T00:00:002020Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement.32969590Al-Adra DP, Hammel L, Roberts J, Woodle ES, Levine D, Mandelbrot D, Verna E, Locke J, D'Cunha J, Farr M, Sawinski D, Agarwal PK, Plichta J, Pruthi S, Farr D, Carvajal R, Walker J, Zwald F, Habermann T, Gertz M, Bierman P, Dizon DS, Langstraat C, Al-Qaoud T, Eggener S, Richgels JP, Chang GJ, Geltzeiler C, Sapisochin G, Ricciardi R, Krupnick AS, Kennedy C, Mohindra N, Foley DP, Watt KDAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant SurgeonsPretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. Am J Transplant. 2021 02; 21(2):460-474.Am J Transplant2020-10-23T00:00:002020Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement.Authorship 1413122433021440Klotz L, Pavlovich CP, Chin J, Hatiboglu G, Koch M, Penson D, Raman S, Oto A, Fütterer J, Serrallach M, Relle J, Lotan Y, Heidenreich A, Bonekamp D, Haider M, Tirkes T, Arora S, Macura KJ, Costa DN, Persigehl T, Pantuck AJ, Bomers J, Burtnyk M, Staruch R, Eggener SThe Journal of urologyMagnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. J Urol. 2021 Mar; 205(3):769-779.J Urol2020-10-06T00:00:002020Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer.9582053Eggener SJAMAThe power of the pen: medical journalism and public awareness. JAMA. 1998 May 06; 279(17):1400.JAMA1998-05-06T00:00:001998The power of the pen: medical journalism and public awareness.Authorship 1416751033088675Press DJ, Pierce B, Lauderdale DS, Aschebrook-Kilfoy B, Lin Gomez S, Hedeker D, Wright NE, Fantus RJ, Bettencourt L, Ahsan H, Eggener SPreventive medicine reportsTobacco and marijuana use and their association with serum prostate-specific antigen levels among African American men in Chicago. Prev Med Rep. 2020 Dec; 20:101174.Prev Med Rep2020-08-11T00:00:002020Tobacco and marijuana use and their association with serum prostate-specific antigen levels among African American men in Chicago.Authorship 141802833121935Saoud RM, Andolfi C, Aizen J, Wymer K, Burg M, Barashi N, Daneshmand S, Eggener SEuropean urology focusImpact of Non-guideline-directed Care on Quality of Life in Testicular Cancer Survivors. Eur Urol Focus. 2021 Sep; 7(5):1137-1142.Eur Urol Focus2020-10-26T00:00:002020Impact of Non-guideline-directed Care on Quality of Life in Testicular Cancer Survivors.11880093Rubenstein JN, Hairston JC, Eggener SE, Gonzalez CMUrologyIrritative voiding symptoms and microscopic hematuria caused by intraperitoneal calcified fat necrosis. Urology. 2002 Mar; 59(3):444.Urology2002-03-01T00:00:002002Irritative voiding symptoms and microscopic hematuria caused by intraperitoneal calcified fat necrosis.11547089Eggener SE, Hairston J, Rubenstein JN, Gonzalez CMThe Journal of urologyBladder lipoma. J Urol. 2001 Oct; 166(4):1395.J Urol2001-10-01T00:00:002001Bladder lipoma.Authorship 142439733257031Shi Z, Platz EA, Wei J, Na R, Fantus RJ, Wang CH, Eggener SE, Hulick PJ, Duggan D, Zheng SL, Cooney KA, Isaacs WB, Helfand BT, Xu JEuropean urologyPerformance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis. Eur Urol. 2021 03; 79(3):419-426.Eur Urol2020-11-28T00:00:002020Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis.Authorship 142591133303242Eggener SE, Agarwal PKEuropean urologyRe: Pretransplant Solid Organ Malignancy and Organ Transplant Candidacy: A Consensus Expert Opinion Statement. Eur Urol. 2021 04; 79(4):552-553.Eur Urol2020-12-07T00:00:002020Re: Pretransplant Solid Organ Malignancy and Organ Transplant Candidacy: A Consensus Expert Opinion Statement.12629332Smith ND, Rubenstein JN, Eggener SE, Kozlowski JMThe Journal of urologyThe p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol. 2003 Apr; 169(4):1219-28.J Urol2003-04-01T00:00:002003The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.11999473Brooks JD, Eggener SE, Chao WMEuropean urologyAnatomy of the rectourethralis muscle. Eur Urol. 2002 Jan; 41(1):94-100.Eur Urol2002-01-01T00:00:002002Anatomy of the rectourethralis muscle.12429336Rodriguez HE, Eggener SE, Podbielski FJ, Brown AM, Amble S, Clark ET, Smith NDUrologyOcclusion of an intraluminal endovascular stent graft after treatment of a ureteral-iliac artery fistula. Urology. 2002 Nov; 60(5):912.Urology2002-11-01T00:00:002002Occlusion of an intraluminal endovascular stent graft after treatment of a ureteral-iliac artery fistula.12544290Nadler RB, Rubenstein JN, Eggener SE, Loor MM, Smith NDThe Journal of urologyThe etiology of urolithiasis in HIV infected patients. J Urol. 2003 Feb; 169(2):475-7.J Urol2003-02-01T00:00:002003The etiology of urolithiasis in HIV infected patients.Authorship 1430012433355501Klotz L, Pavlovich CP, Chin J, Hatiboglu G, Koch M, Penson D, Raman S, Oto A, Fütterer J, Serrallach M, Relle J, Lotan Y, Heidenreich A, Bonekamp D, Haider M, Tirkes T, Arora S, Macura KJ, Costa DN, Persigehl T, Pantuck AJ, Bomers J, Burtnyk M, Staruch R, Eggener SThe Journal of urologyReply by Authors. J Urol. 2021 03; 205(3):779.J Urol2020-12-23T00:00:002020Reply by Authors.14566143Eggener SE, Stern JA, Smith ND, Gonzalez CMThe Journal of traumaPenile refracture: case report. J Trauma. 2003 Oct; 55(4):793-4.J Trauma2003-10-01T00:00:002003Penile refracture: case report.11832772Reiher F, Ozer O, Pins M, Jovanovic BD, Eggener S, Campbell SCThe Journal of urologyp53 and microvessel density in primary resection specimens of superficial bladder cancer. J Urol. 2002 Mar; 167(3):1469-74.J Urol2002-03-01T00:00:002002p53 and microvessel density in primary resection specimens of superficial bladder cancer.12385938Raviv S, Eggener SE, Williams DH, Garnett JE, Pins MR, Smith NDUrologyLong-term survival after "drop metastases" of renal cell carcinoma to the bladder. Urology. 2002 Oct; 60(4):697.Urology2002-10-01T00:00:002002Long-term survival after "drop metastases" of renal cell carcinoma to the bladder.15821574Eggener SE, Lotan Y, Cheng EYThe Journal of urologyMagnetic resonance angiography for the nonpalpable testis: a cost and cancer risk analysis. J Urol. 2005 May; 173(5):1745-9; discussion 1749-50.J Urol2005-05-01T00:00:002005Magnetic resonance angiography for the nonpalpable testis: a cost and cancer risk analysis.Authorship 143257333432506Labbate CV, Paner GP, Eggener SEWorld journal of urologyShould Grade Group 1 (GG1) be called cancer? World J Urol. 2022 Jan; 40(1):15-19.World J Urol2021-01-11T00:00:002021Should Grade Group 1 (GG1) be called cancer?15758725Eggener SE, Roehl KA, Smith ND, Antenor JA, Han M, Catalona WJThe Journal of urologyContemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy. J Urol. 2005 Apr; 173(4):1150-5.J Urol2005-04-01T00:00:002005Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy.15992903Antenor JA, Roehl KA, Eggener SE, Kundu SD, Han M, Catalona WJUrologyPreoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease. Urology. 2005 Jul; 66(1):156-60.Urology2005-07-01T00:00:002005Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease.16006880Eggener SE, Roehl KA, Catalona WJThe Journal of urologyPredictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy. J Urol. 2005 Aug; 174(2):500-4.J Urol2005-08-01T00:00:002005Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy.Medicine-Hematology and Oncology17113889Pettus JA, Eggener SE, Shabsigh A, Yanke B, Snyder ME, Serio A, Vickers A, Russo P, Donat SMUrologyPerioperative clinical thromboembolic events after radical or partial nephrectomy. Urology. 2006 Nov; 68(5):988-92.Urology2006-11-01T00:00:002006Perioperative clinical thromboembolic events after radical or partial nephrectomy.17561152Yossepowitch O, Eggener SE, Bianco FJ, Carver BS, Serio A, Scardino PT, Eastham JAThe Journal of urologyRadical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol. 2007 Aug; 178(2):493-9; discussion 499.J Urol2007-06-11T00:00:002007Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.16372330Eggener SE, Stern JA, Jain PM, Oram S, Ai J, Cai X, Roehl KA, Wang ZThe ProstateEnhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model. Prostate. 2006 Apr 01; 66(5):495-502.Prostate2006-04-01T00:00:002006Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model.16809736Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo PJournal of clinical oncology : official journal of the American Society of Clinical OncologyRenal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol. 2006 Jul 01; 24(19):3101-6.J Clin Oncol2006-07-01T00:00:002006Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence.16820545Eggener S, Herr HJAMANMP22 and surveillance for recurrent bladder cancer. JAMA. 2006 Jul 05; 296(1):45; author reply 45-6.JAMA2006-07-05T00:00:002006NMP22 and surveillance for recurrent bladder cancer.14665855Eggener SE, Rubenstein JN, Smith ND, Nadler RB, Kontak J, Flanigan RC, Waters WB, Picken M, Campbell SC, Rubenstein JRThe Journal of urologyRenal tumors in young adults. J Urol. 2004 Jan; 171(1):106-10.J Urol2004-01-01T00:00:002004Renal tumors in young adults.17786183Oram SW, Ai J, Pagani GM, Hitchens MR, Stern JA, Eggener S, Pins M, Xiao W, Cai X, Haleem R, Jiang F, Pochapsky TC, Hedstrom L, Wang ZNeoplasia (New York, N.Y.)Expression and function of the human androgen-responsive gene ADI1 in prostate cancer. Neoplasia. 2007 Aug; 9(8):643-51.Neoplasia2007-08-01T00:00:002007Expression and function of the human androgen-responsive gene ADI1 in prostate cancer.15245959Thaxton CS, Eggener SE, Schaeffer AJUrologyPlasma cell infiltration of the urinary bladder. Urology. 2004 Jul; 64(1):156-7.Urology2004-07-01T00:00:002004Plasma cell infiltration of the urinary bladder.17936815Eggener SE, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O, Hricak H, Wheeler TM, Fine SW, Trachtenberg J, Rubin MA, Ohori M, Kuroiwa K, Rossignol M, Abenhaim L, International Task Force on Prostate Cancer and the Focal Lesion ParadigmThe Journal of urologyFocal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007 Dec; 178(6):2260-7.J Urol2007-10-15T00:00:002007Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.MichaelDrazerMichael Drazer41.7886000000000087.598699999999994000Drazer, MichaelAssistant ProfessorAuthorship 144509733608234Vickers AJ, Russo G, Lilja H, Evans C, Schalken JA, Klein E, Eggener SEuropean urology oncologyHow Should Molecular Markers and Magnetic Resonance Imaging Be Used in the Early Detection of Prostate Cancer? Eur Urol Oncol. 2022 04; 5(2):135-137.Eur Urol Oncol2021-02-16T00:00:002021How Should Molecular Markers and Magnetic Resonance Imaging Be Used in the Early Detection of Prostate Cancer?12913729Eggener SE, Hua V, Schaeffer AJ, Smith NDThe Journal of urologyA noninfectious source of renal gas: embolization. J Urol. 2003 Sep; 170(3):913.J Urol2003-09-01T00:00:002003A noninfectious source of renal gas: embolization.16952643Eggener SE, Roehl KA, Yossepowitch O, Catalona WJThe Journal of urologyPrediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. J Urol. 2006 Oct; 176(4 Pt 1):1399-403.J Urol2006-10-01T00:00:002006Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.16985680Rubenstein JN, Eggener SE, Pins MR, Rosner K, Chugh S, Campbell SCReviews in urologyJuxtaglomerular apparatus tumor: a rare, surgically correctable cause of hypertension. Rev Urol. 2002; 4(4):192-5.Rev Urol2002-01-01T00:00:002002Juxtaglomerular apparatus tumor: a rare, surgically correctable cause of hypertension.17177200Eggener SE, Carver BS, Loeb S, Kondagunta GV, Bosl GJ, Sheinfeld JCancerPathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. Cancer. 2007 Feb 01; 109(3):528-35.Cancer2007-02-01T00:00:002007Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors.17950521Yossepowitch O, Eggener SE, Serio AM, Carver BS, Bianco FJ, Scardino PT, Eastham JAEuropean urologySecondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol. 2008 May; 53(5):950-9.Eur Urol2007-10-12T00:00:002007Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy.18339477Eggener SE, Guillonneau BEuropean urologyLaparoscopic radical prostatectomy: ten years later, time for evidence-based foundation. Eur Urol. 2008 Jul; 54(1):4-7.Eur Urol2008-03-05T00:00:002008Laparoscopic radical prostatectomy: ten years later, time for evidence-based foundation.18423758Yossepowitch O, Thompson RH, Leibovich BC, Eggener SE, Pettus JA, Kwon ED, Herr HW, Blute ML, Russo PThe Journal of urologyPositive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol. 2008 Jun; 179(6):2158-63.J Urol2008-06-01T00:00:002008Positive surgical margins at partial nephrectomy: predictors and oncological outcomes.19091455Eggener SEEuropean urologyEditorial comment on: Reducing laparoscopic radical prostatectomy false-positive margin rates using cyanoacrylate tissue glue. Eur Urol. 2009 Oct; 56(4):658.Eur Urol2008-12-10T00:00:002008Editorial comment on: Reducing laparoscopic radical prostatectomy false-positive margin rates using cyanoacrylate tissue glue.18635225Eggener SE, Yossepowitch O, Kundu S, Motzer RJ, Russo PThe Journal of urologyRisk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol. 2008 Sep; 180(3):873-8; discussion 878.J Urol2008-07-17T00:00:002008Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma.15003200Eggener SE, Dalton DPThe Lancet. OncologyBilateral pulmonary artery tumour emboli from renal carcinoma. Lancet Oncol. 2004 Mar; 5(3):173.Lancet Oncol2004-03-01T00:00:002004Bilateral pulmonary artery tumour emboli from renal carcinoma.15028471Eggener SE, Abrahams A, Keeler TCUrologyGranulocytic sarcoma of the testis. Urology. 2004 Mar; 63(3):584-5.Urology2004-03-01T00:00:002004Granulocytic sarcoma of the testis.17933029Eggener SEuropean urologyEditorial comment on: Methods of calculating prostate-specific antigen velocity. Eur Urol. 2007 Oct; 52(4):1050-1.Eur Urol2007-10-01T00:00:002007Editorial comment on: Methods of calculating prostate-specific antigen velocity.15538237Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona WJThe Journal of urologyPotency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol. 2004 Dec; 172(6 Pt 1):2227-31.J Urol2004-12-01T00:00:002004Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies.19190765Kundu SD, Eggener SEAdvances in urologyRetroperitoneal lymph nodes in transitional cell carcinoma of the kidney and ureter. Adv Urol. 2009; 181927.Adv Urol2009-01-26T00:00:002009Retroperitoneal lymph nodes in transitional cell carcinoma of the kidney and ureter.18936477Sharp DS, Carver BS, Eggener SE, Kondagunta GV, Motzer RJ, Bosl GJ, Sheinfeld JJournal of clinical oncology : official journal of the American Society of Clinical OncologyClinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol. 2008 Dec 01; 26(34):5524-9.J Clin Oncol2008-10-20T00:00:002008Clinical outcome and predictors of survival in late relapse of germ cell tumor.19467770Eggener SEEuropean urologyEditorial comment on: Perioperative morbidity of laparoscopic cryoablation of small renal masses with ultrathin probes: a European multicentre experience. Eur Urol. 2009 Aug; 56(2):361-2.Eur Urol2009-05-13T00:00:002009Editorial comment on: Perioperative morbidity of laparoscopic cryoablation of small renal masses with ultrathin probes: a European multicentre experience.15707510Eggener S, Kim SC, User HM, Pazona J, Nadler RBInternational braz j urol : official journal of the Brazilian Society of UrologyUrolithiasis associated with topiramate. Int Braz J Urol. 2004 Jan-Feb; 30(1):29-30; discussion 30-1.Int Braz J Urol2004-01-01T00:00:002004Urolithiasis associated with topiramate.19530906Shikanov S, Wille M, Large M, Lifshitz DA, Zorn KC, Shalhav AL, Eggener SEJournal of endourologyKnotless closure of the collecting system and renal parenchyma with a novel barbed suture during laparoscopic porcine partial nephrectomy. J Endourol. 2009 Jul; 23(7):1157-60.J Endourol2009-07-01T00:00:002009Knotless closure of the collecting system and renal parenchyma with a novel barbed suture during laparoscopic porcine partial nephrectomy.18470927Russo P, Jang TL, Pettus JA, Huang WC, Eggener SE, O'Brien MF, Karellas ME, Karanikolas NT, Kagiwada MACancerSurvival rates after resection for localized kidney cancer: 1989 to 2004. Cancer. 2008 Jul 01; 113(1):84-96.Cancer2008-07-01T00:00:002008Survival rates after resection for localized kidney cancer: 1989 to 2004.18836668Eggener SE, Coleman JATheScientificWorldJournalFocal treatment of prostate cancer with vascular-targeted photodynamic therapy. ScientificWorldJournal. 2008 Oct 03; 8:963-73.ScientificWorldJournal2008-10-03T00:00:002008Focal treatment of prostate cancer with vascular-targeted photodynamic therapy.18930486Thong AE, Shikanov S, Katz MH, Gofrit ON, Eggener S, Zagaja GP, Shalhav AL, Zorn KCThe Journal of urologyA single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes? J Urol. 2008 Dec; 180(6):2436-40.J Urol2008-10-19T00:00:002008A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes?19359087Eggener SEuropean urologyEditorial comment on: Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol. 2010 Mar; 57(3):472.Eur Urol2009-03-31T00:00:002009Editorial comment on: Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery.19608864Alur M, Nguyen MM, Eggener SE, Jiang F, Dadras SS, Stern J, Kimm S, Roehl K, Kozlowski J, Pins M, Michalak M, Dhir R, Wang ZThe American journal of pathologySuppressive roles of calreticulin in prostate cancer growth and metastasis. Am J Pathol. 2009 Aug; 175(2):882-90.Am J Pathol2009-07-16T00:00:002009Suppressive roles of calreticulin in prostate cancer growth and metastasis.19625032Zorn KC, Gautam G, Shalhav AL, Clayman RV, Ahlering TE, Albala DM, Lee DI, Sundaram CP, Matin SF, Castle EP, Winfield HN, Gettman MT, Lee BR, Thomas R, Patel VR, Leveillee RJ, Wong C, Badlani GH, Rha KH, Eggener SE, Wiklund P, Mottrie A, Atug F, Kural AR, Joseph JV, Members of the Society of Urologic Robotic SurgeonsThe Journal of urologyTraining, credentialing, proctoring and medicolegal risks of robotic urological surgery: recommendations of the society of urologic robotic surgeons. J Urol. 2009 Sep; 182(3):1126-32.J Urol2009-07-21T00:00:002009Training, credentialing, proctoring and medicolegal risks of robotic urological surgery: recommendations of the society of urologic robotic surgeons.19467675Eggener SE, Raman JDThe Journal of urologyRe: Effectiveness of antibiotics given to asymptomatic men for an increased prostate specific antigen. S. Baltaci, E. Suer, A. H. Haliloglu, M. I. Gokce, A. H. Elhan and Y. Beduk. J Urol 2009; 181: 128-132. J Urol. 2009 Jul; 182(1):396-7.J Urol2009-05-20T00:00:002009Re: Effectiveness of antibiotics given to asymptomatic men for an increased prostate specific antigen. S. Baltaci, E. Suer, A. H. Haliloglu, M. I. Gokce, A. H. Elhan and Y. Beduk. J Urol 2009; 181: 128-132.19840015Large MC, Sheinfeld J, Eggener SEBJU internationalRetroperitoneal lymph node dissection: reassessment of modified templates. BJU Int. 2009 Nov; 104(9 Pt B):1369-75.BJU Int2009-11-01T00:00:002009Retroperitoneal lymph node dissection: reassessment of modified templates.19171420Reynolds WS, Eggener SEEuropean urologyEditorial comment on: Preservation of lateral prostatic fascia is associated with urine continence after robotic-assisted prostatectomy. Eur Urol. 2009 Apr; 55(4):900-1.Eur Urol2009-01-21T00:00:002009Editorial comment on: Preservation of lateral prostatic fascia is associated with urine continence after robotic-assisted prostatectomy.16952626Yossepowitch O, Eggener SE, Serio A, Huang WC, Snyder ME, Vickers AJ, Russo PThe Journal of urologyTemporary renal ischemia during nephron sparing surgery is associated with short-term but not long-term impairment in renal function. J Urol. 2006 Oct; 176(4 Pt 1):1339-43; discussion 1343.J Urol2006-10-01T00:00:002006Temporary renal ischemia during nephron sparing surgery is associated with short-term but not long-term impairment in renal function.20378241Eggener S, Salomon G, Scardino PT, De la Rosette J, Polascik TJ, Brewster SEuropean urologyFocal therapy for prostate cancer: possibilities and limitations. Eur Urol. 2010 Jul; 58(1):57-64.Eur Urol2010-03-26T00:00:002010Focal therapy for prostate cancer: possibilities and limitations.16280754Nadler RB, Loeb S, Roehl KA, Antenor JA, Eggener S, Catalona WJThe Journal of urologyUse of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years. J Urol. 2005 Dec; 174(6):2154-7, discussion 2157.J Urol2005-12-01T00:00:002005Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years.19363613Katz MH, Eggener SEWorld journal of urologyThe evolution, controversies, and potential pitfalls of modified retroperitoneal lymph node dissection templates. World J Urol. 2009 Aug; 27(4):477-83.World J Urol2009-04-11T00:00:002009The evolution, controversies, and potential pitfalls of modified retroperitoneal lymph node dissection templates.19616257Lifshitz DA, Shikanov S, Jeldres C, Deklaj T, Karakiewicz PI, Zorn KC, Eggener SE, Shalhav ALThe Journal of urologyLaparoscopic partial nephrectomy: predictors of prolonged warm ischemia. J Urol. 2009 Sep; 182(3):860-5.J Urol2009-07-17T00:00:002009Laparoscopic partial nephrectomy: predictors of prolonged warm ischemia.19450829Shikanov S, Song J, Royce C, Al-Ahmadie H, Zorn K, Steinberg G, Zagaja G, Shalhav A, Eggener SThe Journal of urologyLength of positive surgical margin after radical prostatectomy as a predictor of biochemical recurrence. J Urol. 2009 Jul; 182(1):139-44.J Urol2009-05-17T00:00:002009Length of positive surgical margin after radical prostatectomy as a predictor of biochemical recurrence.16813873Yossepowitch O, Eggener SE, Bochner BH, Donat SM, Herr HW, Dalbagni GThe Journal of urologySafety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients. J Urol. 2006 Aug; 176(2):482-5.J Urol2006-08-01T00:00:002006Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.Authorship 146058933872561Asghar AM, McIntosh AG, Smith ZL, Kocher NJ, Lee Z, Barashi NN, Li T, Raman JD, Eggener SE, Uzzo RG, Kutikov AThe Canadian journal of urologyPathological characteristics of the large renal mass: potential implication for clinical role of renal biopsy. Can J Urol. 2021 04; 28(2):10620-10624.Can J Urol2021-04-01T00:00:002021Pathological characteristics of the large renal mass: potential implication for clinical role of renal biopsy.D017430Chemicals & Drugs953460.825491Prostate-Specific Antigen19962732Lifshitz DA, Shikanov SA, Deklaj T, Katz MH, Zorn KC, Eggener SE, Shalhav ALUrologyLaparoscopic partial nephrectomy: a single-center evolving experience. Urology. 2010 Feb; 75(2):282-7.Urology2009-12-04T00:00:002009Laparoscopic partial nephrectomy: a single-center evolving experience.20299052Shikanov S, Lifshitz D, Chan AA, Okhunov Z, Ordonez MA, Wheat JC, Matin SF, Landman J, Wolf JS, Eggener SE, Shalhav ALThe Journal of urologyImpact of ischemia on renal function after laparoscopic partial nephrectomy: a multicenter study. J Urol. 2010 May; 183(5):1714-8.J Urol2010-03-17T00:00:002010Impact of ischemia on renal function after laparoscopic partial nephrectomy: a multicenter study.20478585Brien JC, Shariat SF, Herman MP, Ng CK, Scherr DS, Scoll B, Uzzo RG, Wille M, Eggener SE, Terrell JD, Lucas SM, Lotan Y, Boorjian SA, Raman JDThe Journal of urologyPreoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol. 2010 Jul; 184(1):69-73.J Urol2010-05-15T00:00:002010Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma.20850146Gautam G, Lifshitz D, Shikanov S, Moore JM, Eggener SE, Shalhav AL, Chang AThe Journal of urologyHistopathological predictors of renal function decrease after laparoscopic radical nephrectomy. J Urol. 2010 Nov; 184(5):1872-6.J Urol2010-09-17T00:00:002010Histopathological predictors of renal function decrease after laparoscopic radical nephrectomy.17634540Bjartell AS, Al-Ahmadie H, Serio AM, Eastham JA, Eggener SE, Fine SW, Udby L, Gerald WL, Vickers AJ, Lilja H, Reuter VE, Scardino PTClinical cancer research : an official journal of the American Association for Cancer ResearchAssociation of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res. 2007 Jul 15; 13(14):4130-8.Clin Cancer Res2007-07-15T00:00:002007Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy.19200640Orvieto M, Eggener SEuropean urologyEditorial comment on: Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol. 2009 May; 55(5):1073-4.Eur Urol2009-02-05T00:00:002009Editorial comment on: Pharmacological approaches to reducing the risk of prostate cancer.22052762Marchetti P, Eggener SArchivos espanoles de urologiaFocal therapy for clinically localized prostate cancer. Arch Esp Urol. 2011 Oct; 64(8):815-22.Arch Esp Urol2011-10-01T00:00:002011Focal therapy for clinically localized prostate cancer.21334019Eggener SThe Journal of urologyEditorial comment. J Urol. 2011 Apr; 185(4):1254-5.J Urol2011-02-22T00:00:002011Editorial comment.19913836Large MC, Katz MH, Shikanov S, Eggener SE, Steinberg GDThe Journal of urologyOrthotopic neobladder versus Indiana pouch in women: a comparison of health related quality of life outcomes. J Urol. 2010 Jan; 183(1):201-6.J Urol2010-01-01T00:00:002010Orthotopic neobladder versus Indiana pouch in women: a comparison of health related quality of life outcomes.22498216Patel AR, Prasad SM, Shih YC, Eggener SEThe Journal of urologyThe association of the human development index with global kidney cancer incidence and mortality. J Urol. 2012 Jun; 187(6):1978-83.J Urol2012-04-11T00:00:002012The association of the human development index with global kidney cancer incidence and mortality.Authorship 146872134074115Eggener SEThe Journal of urologyEditorial Comment. J Urol. 2021 09; 206(3):668.J Urol2021-06-02T00:00:002021Editorial Comment.21928309Fan X, Haney CR, Agrawal G, Pelizzari CA, Antic T, Eggener SE, Sethi I, River JN, Zamora M, Karczmar GS, Oto AJournal of magnetic resonance imaging : JMRIHigh-resolution MRI of excised human prostate specimens acquired with 9.4T in detection and identification of cancers: validation of a technique. J Magn Reson Imaging. 2011 Oct; 34(4):956-61.J Magn Reson Imaging2011-10-01T00:00:002011High-resolution MRI of excised human prostate specimens acquired with 9.4T in detection and identification of cancers: validation of a technique.22083265Shikanov S, Kocherginsky M, Shalhav AL, Eggener SEProstate cancer and prostatic diseasesCause-specific mortality following radical prostatectomy. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):106-10.Prostate Cancer Prostatic Dis2011-11-15T00:00:002011Cause-specific mortality following radical prostatectomy.22109293Oto A, Yang C, Kayhan A, Tretiakova M, Antic T, Schmid-Tannwald C, Eggener S, Karczmar GS, Stadler WMAJR. American journal of roentgenologyDiffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol. 2011 Dec; 197(6):1382-90.AJR Am J Roentgenol2011-12-01T00:00:002011Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis.22385991Meeks JJ, Sheinfeld J, Eggener SEUrologic oncologyEnvironmental toxicology of testicular cancer. Urol Oncol. 2012 Mar-Apr; 30(2):212-5.Urol Oncol2012-03-01T00:00:002012Environmental toxicology of testicular cancer.22582361Yacoub JH, Verma S, Moulton JS, Eggener S, Aytekin ORadiographics : a review publication of the Radiological Society of North America, IncImaging-guided prostate biopsy: conventional and emerging techniques. Radiographics. 2012 May-Jun; 32(3):819-37.Radiographics2012-05-01T00:00:002012Imaging-guided prostate biopsy: conventional and emerging techniques.22704316Eggener SThe Canadian journal of urologyRe: Active surveillance failure for prostate cancer: does the delay in treatment increase the risk of urinary incontinence? Can J Urol. 2012 Jun; 19(3):6292.Can J Urol2012-06-01T00:00:002012Re: Active surveillance failure for prostate cancer: does the delay in treatment increase the risk of urinary incontinence?21320275Messer J, Shariat SF, Brien JC, Herman MP, Ng CK, Scherr DS, Scoll B, Uzzo RG, Wille M, Eggener SE, Steinberg G, Terrell JD, Lucas SM, Lotan Y, Boorjian SA, Raman JDBJU internationalUrinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int. 2011 Sep; 108(5):701-5.BJU Int2011-02-14T00:00:002011Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma.Authorship 147180434128116Tatjana A, Tjota MY, O'Donnell PH, Eggener SE, Agarwal PK, Haridas R, Segal J, Wang PVirchows Archiv : an international journal of pathologyEZR-ROS1 fusion renal cell carcinoma mimicking urothelial carcinoma: report of a previously undescribed gene fusion in renal cell carcinoma. Virchows Arch. 2022 Feb; 480(2):487-492.Virchows Arch2021-06-14T00:00:002021EZR-ROS1 fusion renal cell carcinoma mimicking urothelial carcinoma: report of a previously undescribed gene fusion in renal cell carcinoma.18538735Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F, Helgeson BE, Laxman B, Morris DS, Cao Q, Cao X, Andrén O, Fall K, Johnson L, Wei JT, Shah RB, Al-Ahmadie H, Eastham JA, Eggener SE, Fine SW, Hotakainen K, Stenman UH, Tsodikov A, Gerald WL, Lilja H, Reuter VE, Kantoff PW, Scardino PT, Rubin MA, Bjartell AS, Chinnaiyan AMCancer cellThe role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell. 2008 Jun; 13(6):519-28.Cancer Cell2008-06-01T00:00:002008The role of SPINK1 in ETS rearrangement-negative prostate cancers.18639973Eggener SEuropean urologyEditorial comment on: Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels. Eur Urol. 2009 Mar; 55(3):616.Eur Urol2008-07-14T00:00:002008Editorial comment on: Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels.18801515Berglund RK, Masterson TA, Vora KC, Eggener SE, Eastham JA, Guillonneau BDThe Journal of urologyPathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol. 2008 Nov; 180(5):1964-7; discussion 1967-8.J Urol2008-09-17T00:00:002008Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance.20299079Carver BS, Cronin AM, Eggener S, Savage CJ, Motzer RJ, Bajorin D, Bosl GJ, Sheinfeld JUrologyThe total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer. Urology. 2010 Jun; 75(6):1431-5.Urology2010-03-17T00:00:002010The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer.16000589Eigl BJ, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C, Wang Z, Gleave MEClinical cancer research : an official journal of the American Association for Cancer ResearchTiming is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res. 2005 Jul 01; 11(13):4905-11.Clin Cancer Res2005-07-01T00:00:002005Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.19947349Large MC, Eggener SEOncology (Williston Park, N.Y.)Active surveillance for low-risk localized prostate cancer. Oncology (Williston Park). 2009 Oct; 23(11):974-9.Oncology (Williston Park)2009-10-01T00:00:002009Active surveillance for low-risk localized prostate cancer.22192113Clements T, Messer JC, Terrell JD, Herman MP, Ng CK, Scherr DS, Scoll B, Boorjian SA, Uzzo RG, Wille M, Eggener SE, Lucas SM, Lotan Y, Shariat SF, Raman JDJournal of endourologyHigh-grade ureteroscopic biopsy is associated with advanced pathology of upper-tract urothelial carcinoma tumors at definitive surgical resection. J Endourol. 2012 Apr; 26(4):398-402.J Endourol2012-02-24T00:00:002012High-grade ureteroscopic biopsy is associated with advanced pathology of upper-tract urothelial carcinoma tumors at definitive surgical resection.20846677Shikanov S, Clark MA, Raman JD, Smith B, Kaag M, Russo P, Wheat JC, Wolf JS, Huang WC, Shalhav AL, Eggener SEThe Journal of urologyChronic Kidney Disease Epidemiology Collaboration versus Modification of Diet in Renal Disease equations for renal function evaluation in patients undergoing partial nephrectomy. J Urol. 2010 Nov; 184(5):1867-71.J Urol2010-09-17T00:00:002010Chronic Kidney Disease Epidemiology Collaboration versus Modification of Diet in Renal Disease equations for renal function evaluation in patients undergoing partial nephrectomy.21444863Drazer MW, Huo D, Schonberg MA, Razmaria A, Eggener SEJournal of clinical oncology : official journal of the American Society of Clinical OncologyPopulation-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol. 2011 May 01; 29(13):1736-43.J Clin Oncol2011-03-28T00:00:002011Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States.21612857Rosen A, Jayram G, Drazer M, Eggener SEEuropean urologyGlobal trends in testicular cancer incidence and mortality. Eur Urol. 2011 Aug; 60(2):374-9.Eur Urol2011-05-17T00:00:002011Global trends in testicular cancer incidence and mortality.Authorship 148306434317194Ali W, Nathan S, Funaki B, Eggener S, Bakris GJACC. Case reportsAn Unusual Case of Resistant Hypertension Secondary to Fibromuscular Dysplasia. JACC Case Rep. 2020 Dec; 2(15):2460-2464.JACC Case Rep2020-10-28T00:00:002020An Unusual Case of Resistant Hypertension Secondary to Fibromuscular Dysplasia.22114813Shikanov S, Eggener SEThe Journal of urologyHazard of prostate cancer specific mortality after radical prostatectomy. J Urol. 2012 Jan; 187(1):124-7.J Urol2011-11-23T00:00:002011Hazard of prostate cancer specific mortality after radical prostatectomy.22462566Smeenge M, Barentsz J, Cosgrove D, de la Rosette J, de Reijke T, Eggener S, Frauscher F, Kovacs G, Matin SF, Mischi M, Pinto P, Rastinehad A, Rouviere O, Salomon G, Polascik T, Walz J, Wijkstra H, Marberger MBJU internationalRole of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel. BJU Int. 2012 Oct; 110(7):942-8.BJU Int2012-03-30T00:00:002012Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel.21797760Lifshitz DA, Shikanov SA, Razmaria AA, Eggener SE, Liao C, Chang A, Shalhav ALJournal of endourologyClinical and histologic predictors of renal function decline after laparoscopic partial nephrectomy. J Endourol. 2011 Sep; 25(9):1435-41.J Endourol2011-07-28T00:00:002011Clinical and histologic predictors of renal function decline after laparoscopic partial nephrectomy.22535850Prasad SM, Drazer MW, Huo D, Hu JC, Eggener SEJAMA2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA. 2012 Apr 25; 307(16):1692-4.JAMA2012-04-25T00:00:0020122008 US Preventive Services Task Force recommendations and prostate cancer screening rates.17296380Eggener SE, Carver BS, Sharp DS, Motzer RJ, Bosl GJ, Sheinfeld JThe Journal of urologyIncidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. J Urol. 2007 Mar; 177(3):937-42; discussion 942-3.J Urol2007-03-01T00:00:002007Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer.17572200Eggener SE, Yossepowitch O, Serio AM, Vickers AJ, Scardino PT, Eastham JAUrologyRadical prostatectomy shortly after prostate biopsy does not affect operative difficulty or efficacy. Urology. 2007 Jun; 69(6):1128-33.Urology2007-06-01T00:00:002007Radical prostatectomy shortly after prostate biopsy does not affect operative difficulty or efficacy.7869251Dietz NM, Rivera JM, Eggener SE, Fix RT, Warner DO, Joyner MJThe Journal of physiologyNitric oxide contributes to the rise in forearm blood flow during mental stress in humans. J Physiol. 1994 Oct 15; 480 ( Pt 2):361-8.J Physiol1994-10-15T00:00:001994Nitric oxide contributes to the rise in forearm blood flow during mental stress in humans.17906201Carver BS, Shayegan B, Eggener S, Stasi J, Motzer RJ, Bosl GJ, Sheinfeld JJournal of clinical oncology : official journal of the American Society of Clinical OncologyIncidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol. 2007 Oct 01; 25(28):4365-9.J Clin Oncol2007-10-01T00:00:002007Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.18358515Eggener SE, Yossepowitch O, Roehl KA, Loeb S, Yu X, Catalona WJUrologyRelationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program. Urology. 2008 Jun; 71(6):1016-9.Urology2008-03-21T00:00:002008Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program.18952266Wiltz AL, Shikanov S, Eggener SE, Katz MH, Thong AE, Steinberg GD, Shalhav AL, Zagaja GP, Zorn KCUrologyRobotic radical prostatectomy in overweight and obese patients: oncological and validated-functional outcomes. Urology. 2009 Feb; 73(2):316-22.Urology2008-10-26T00:00:002008Robotic radical prostatectomy in overweight and obese patients: oncological and validated-functional outcomes.19025977Eggener SE, Vickers AJ, Serio AM, Donovan MJ, Khan FM, Bayer-Zubek V, Verbel D, Cordon-Cardo C, Reuter VE, Bianco FJ, Scardino PTCancerComparison of models to predict clinical failure after radical prostatectomy. Cancer. 2009 Jan 15; 115(2):303-10.Cancer2009-01-15T00:00:002009Comparison of models to predict clinical failure after radical prostatectomy.19342957Jayram G, Eggener SECurrent opinion in urologyPatient selection for focal therapy of localized prostate cancer. Curr Opin Urol. 2009 May; 19(3):268-73.Curr Opin Urol2009-05-01T00:00:002009Patient selection for focal therapy of localized prostate cancer.20535293Jayram G, Szmulewitz RZ, Eggener SEIndian journal of urology : IJU : journal of the Urological Society of IndiaManagement of good-risk metastatic nonseminomatous germ cell tumors of the testis: current concepts and controversies. Indian J Urol. 2010 Jan-Mar; 26(1):92-7.Indian J Urol2010-01-01T00:00:002010Management of good-risk metastatic nonseminomatous germ cell tumors of the testis: current concepts and controversies.20728266Eggener SEuropean urologyTNM staging for renal cell carcinoma: time for a new method. Eur Urol. 2010 Oct; 58(4):517-9; discussion 519-21.Eur Urol2010-08-17T00:00:002010TNM staging for renal cell carcinoma: time for a new method.22399364Soylu FN, Eggener S, Oto ADiagnostic and interventional radiology (Ankara, Turkey)Local staging of prostate cancer with MRI. Diagn Interv Radiol. 2012 Jul-Aug; 18(4):365-73.Diagn Interv Radiol2012-03-08T00:00:002012Local staging of prostate cancer with MRI.17125912Yossepowitch O, Bianco FJ, Eggener SE, Eastham JA, Scher HI, Scardino PTEuropean urologyThe natural history of noncastrate metastatic prostate cancer after radical prostatectomy. Eur Urol. 2007 Apr; 51(4):940-7; discussion 947-8.Eur Urol2006-10-30T00:00:002006The natural history of noncastrate metastatic prostate cancer after radical prostatectomy.17138126Roehl KA, Eggener SE, Loeb S, Smith ND, Antenor JA, Catalona WJUrologic oncologySurvival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results. Urol Oncol. 2006 Nov-Dec; 24(6):465-71.Urol Oncol2006-11-01T00:00:002006Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results.Authorship 150639534701117Turchan WT, Cutright D, Wu T, Leng JX, Eggener S, Liauw SInternational journal of radiation oncology, biology, physicsIncidence and Severity of Hematuria After Post-Prostatectomy Radiotherapy in a Cohort With Long-Term Follow-up. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):e296.Int J Radiat Oncol Biol Phys2021-11-01T00:00:002021Incidence and Severity of Hematuria After Post-Prostatectomy Radiotherapy in a Cohort With Long-Term Follow-up.34751615Chatterjee A, Mercado C, Bourne RM, Yousuf A, Hess B, Antic T, Eggener S, Oto A, Karczmar GSRadiologyValidation of Prostate Tissue Composition by Using Hybrid Multidimensional MRI: Correlation with Histologic Findings. Radiology. 2022 02; 302(2):368-377.Radiology2021-11-09T00:00:002021Validation of Prostate Tissue Composition by Using Hybrid Multidimensional MRI: Correlation with Histologic Findings.19165804Eggener SECancerThe clinical diversity of postchemotherapy germ cell teratoma. Cancer. 2009 Mar 15; 115(6):1138-41.Cancer2009-03-15T00:00:002009The clinical diversity of postchemotherapy germ cell teratoma.19233410Eggener SE, Mueller A, Berglund RK, Ayyathurai R, Soloway C, Soloway MS, Abouassaly R, Klein EA, Jones SJ, Zappavigna C, Goldenberg L, Scardino PT, Eastham JA, Guillonneau BThe Journal of urologyA multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol. 2009 Apr; 181(4):1635-41; discussion 1641.J Urol2009-02-23T00:00:002009A multi-institutional evaluation of active surveillance for low risk prostate cancer.19997112Eggener S, Gonzalgo M, Yossepowitch OBritish journal of cancerRegarding: 'High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series'. Br J Cancer. 2009 Dec 15; 101(12):2057-8; author reply 2059.Br J Cancer2009-12-15T00:00:002009Regarding: 'High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series'.21074205Clark MA, Shikanov S, Raman JD, Smith B, Kaag M, Russo P, Wheat JC, Wolf JS, Matin SF, Huang WC, Shalhav AL, Eggener SEThe Journal of urologyChronic kidney disease before and after partial nephrectomy. J Urol. 2011 Jan; 185(1):43-8.J Urol2010-11-12T00:00:002010Chronic kidney disease before and after partial nephrectomy.21226623Katz MH, Shikanov S, Sun M, Abdollah F, Budaeus L, Gong EM, Eggener SE, Steinberg GD, Zagaja GP, Shalhav AL, Karakiewicz PI, Zorn KCJournal of endourologyGleason 6 prostate cancer in one or two biopsy cores can harbor more aggressive disease. J Endourol. 2011 Apr; 25(4):699-703.J Endourol2011-01-12T00:00:002011Gleason 6 prostate cancer in one or two biopsy cores can harbor more aggressive disease.21239008Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, Feng Z, Wood DP, Eastham JA, Yossepowitch O, Rabah DM, Kattan MW, Yu C, Klein EA, Stephenson AJThe Journal of urologyPredicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011 Mar; 185(3):869-75.J Urol2011-01-15T00:00:002011Predicting 15-year prostate cancer specific mortality after radical prostatectomy.22078406Patel AR, Eggener SEUrologic oncologyWarm ischemia less than 30 minutes is not necessarily safe during partial nephrectomy: every minute matters. Urol Oncol. 2011 Nov-Dec; 29(6):826-8.Urol Oncol2011-11-01T00:00:002011Warm ischemia less than 30 minutes is not necessarily safe during partial nephrectomy: every minute matters.Authorship 1509647Authorship 1512036Authorship 151165634815169Saoud R, Kristof TW, Judge C, Chumbalkar V, Antic T, Eggener S, Modi PUrologic oncologyClinical and pathological features of renal epithelioid angiomyolipoma (PEComa): A single institution series. Urol Oncol. 2022 02; 40(2):18-24.Urol Oncol2021-11-20T00:00:002021Clinical and pathological features of renal epithelioid angiomyolipoma (PEComa): A single institution series.34775795Cooperberg MR, Lin DW, Morgan TM, Chapin BF, Chen RC, Eggener SEThe Journal of urologyActive Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer. J Urol. 2022 02; 207(2):262-264.J Urol2021-11-15T00:00:002021Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer.Authorship 151579234895925Grummet J, Eggener SEuropean urologyRe: NCCN Prostate Cancer Guidelines Version 1.2022 - September 10, 2021. Eur Urol. 2022 02; 81(2):218.Eur Urol2021-12-09T00:00:002021Re: NCCN Prostate Cancer Guidelines Version 1.2022 - September 10, 2021.Authorship 1522101Authorship 152306635050703Turchan WT, Cutright D, Wu T, Leng JX, Dignam JJ, Eggener SE, Liauw SLThe Journal of urologyHematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup. J Urol. 2022 06; 207(6):1236-1245.J Urol2022-01-20T00:00:002022Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup.35042391Eggener SThe Journal of urologyEditorial Comment. J Urol. 2022 05; 207(5):1066.J Urol2022-01-19T00:00:002022Editorial Comment.Authorship 152412135080461Eggener S, Siemens DRThe Journal of urologyProstate Cancer, Decisional Regret and Exercise. J Urol. 2022 05; 207(5):952-953.J Urol2022-01-26T00:00:002022Prostate Cancer, Decisional Regret and Exercise.Authorship 153304635236091Turchan WT, Cutright D, Wu T, Leng JX, Dignam JJ, Eggener SE, Liauw SLThe Journal of urologyReply by Authors. J Urol. 2022 06; 207(6):1245.J Urol2022-03-03T00:00:002022Reply by Authors.Authorship 1535962Authorship 1536841435279732Fankhauser CD, Afferi L, Stroup SP, Rocco NR, Olson K, Bagrodia A, Baky F, Cazzaniga W, Mayer E, Nicol D, Islamoglu E, de Vergie S, Saoud R, Eggener SE, Nazzani S, Nicolai N, Hugar L, Sexton WJ, Matei DV, De Cobelli O, Cheaib J, Pierorazio PM, Porter J, Hermanns T, Hamilton RJ, Hiester A, Albers P, Clarke N, Mattei AWorld journal of urologyMinimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. World J Urol. 2022 Jun; 40(6):1505-1512.World J Urol2022-03-13T00:00:002022Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility.35346513Modi PK, Eggener SEEuropean urologyRadical Prostatectomy Without Biopsy: Audacious, Imprudent, or Innovative? Eur Urol. 2022 08; 82(2):161-162.Eur Urol2022-03-25T00:00:002022Radical Prostatectomy Without Biopsy: Audacious, Imprudent, or Innovative?Authorship 1539974Authorship 154227135367082Nyame YA, Cooperberg MR, Cumberbatch MG, Eggener SE, Etzioni R, Gomez SL, Haiman C, Huang F, Lee CT, Litwin MS, Lyratzopoulos G, Mohler JL, Murphy AB, Pettaway C, Powell IJ, Sasieni P, Schaeffer EM, Shariat SF, Gore JLEuropean urologyDeconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. Eur Urol. 2022 10; 82(4):341-351.Eur Urol2022-03-30T00:00:002022Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care.35436144Eggener SE, Berlin A, Vickers AJ, Paner GP, Wolinsky H, Cooperberg MRJournal of clinical oncology : official journal of the American Society of Clinical OncologyLow-Grade Prostate Cancer: Time to Stop Calling It Cancer. J Clin Oncol. 2022 09 20; 40(27):3110-3114.J Clin Oncol2022-04-18T00:00:002022Low-Grade Prostate Cancer: Time to Stop Calling It Cancer.D011468Procedures824570.761125ProstatectomyAuthorship 1547307Authorship 1548327Authorship 154831735536148Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, Eggener S, Horwitz EM, Kane CJ, Kirkby E, Lin DW, McBride SM, Morgans AK, Pierorazio PM, Rodrigues G, Wong WW, Boorjian SAThe Journal of urologyClinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up. J Urol. 2022 07; 208(1):19-25.J Urol2022-05-10T00:00:002022Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up.35536141Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, Eggener S, Horwitz EM, Kane CJ, Kirkby E, Lin DW, McBride SM, Morgans AK, Pierorazio PM, Rodrigues G, Wong WW, Boorjian SAThe Journal of urologyClinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions. J Urol. 2022 07; 208(1):26-33.J Urol2022-05-10T00:00:002022Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions.35536144Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, Eggener S, Horwitz EM, Kane CJ, Kirkby E, Lin DW, McBride SM, Morgans AK, Pierorazio PM, Rodrigues G, Wong WW, Boorjian SAThe Journal of urologyClinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. J Urol. 2022 07; 208(1):10-18.J Urol2022-05-10T00:00:002022Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management.Authorship 155853735790788Gupta N, Patel HD, Taylor J, Borin JF, Jacobsohn K, Kenfield SA, Eggener SE, Price C, Davuluri M, Byrne N, Bivalacqua TJ, Loeb SProstate cancer and prostatic diseasesSystematic review of the impact of a plant-based diet on prostate cancer incidence and outcomes. Prostate Cancer Prostatic Dis. 2022 09; 25(3):444-452.Prostate Cancer Prostatic Dis2022-07-05T00:00:002022Systematic review of the impact of a plant-based diet on prostate cancer incidence and outcomes.Authorship 156165835850677Meza J, Babajide R, Saoud R, Sweis J, Abelleira J, Helenowski I, Jovanovic B, Eggener S, Miller FH, Horowitz JM, Casalino DD, Murphy ABBMC urologyAssessing the accuracy of multiparametric MRI to predict clinically significant prostate cancer in biopsy naïve men across racial/ethnic groups. BMC Urol. 2022 Jul 18; 22(1):107.BMC Urol2022-07-18T00:00:002022Assessing the accuracy of multiparametric MRI to predict clinically significant prostate cancer in biopsy naïve men across racial/ethnic groups.TedSkolarusTed Skolarus41.7886000000000087.598699999999994249Skolarus, TedProfessor24656772Li G, Ci W, Karmakar S, Chen K, Dhar R, Fan Z, Guo Z, Zhang J, Ke Y, Wang L, Zhuang M, Hu S, Li X, Zhou L, Li X, Calabrese MF, Watson ER, Prasad SM, Rinker-Schaeffer C, Eggener SE, Stricker T, Tian Y, Schulman BA, Liu J, White KPCancer cellSPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer. Cancer Cell. 2014 Apr 14; 25(4):455-68.Cancer Cell2014-03-20T00:00:002014SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer.Authorship 1592813Authorship 1599715Authorship 16021413Authorship 1602541Authorship 1583519Authorship 158699635987380Andolfi C, Vickers AJ, Cooperberg MR, Carroll PR, Cowan JE, Paner GP, Helfand BT, Liauw SL, Eggener SEUrologyBlood Prostate-specific Antigen by Volume of Benign, Gleason Pattern 3 and 4 Prostate Tissue. Urology. 2022 12; 170:154-160.Urology2022-08-17T00:00:002022Blood Prostate-specific Antigen by Volume of Benign, Gleason Pattern 3 and 4 Prostate Tissue.36459669Eggener SE, Berlin A, Vickers AJ, Paner GP, Wolinsky H, Cooperberg MRJournal of clinical oncology : official journal of the American Society of Clinical OncologyReply to M. Baboudjian et al. J Clin Oncol. 2023 Mar 01; 41(7):1493-1494.J Clin Oncol2022-12-02T00:00:002022Reply to M. Baboudjian et al.36280498Vickers AJ, Cooperberg MR, Eggener SEEuropean urologyRemoving the Designation of Cancer from Grade Group 1 Disease Will Do More Good than Harm. Eur Urol. 2023 04; 83(4):304-306.Eur Urol2022-10-21T00:00:002022Removing the Designation of Cancer from Grade Group 1 Disease Will Do More Good than Harm.36437156Ghoreifi A, Mitra AP, McClintock G, Baky F, McDowell Z, Lavallée E, Saoud R, Cai J, Gill IS, Sfakianos J, Porter J, Bagrodia A, Ahmadi N, Eggener S, Ward JF, Djaladat HUrologic oncologyRobotic post-chemotherapy retroperitoneal lymph node dissection for testicular cancer: A multicenter collaborative study. Urol Oncol. 2023 02; 41(2):111.e7-111.e14.Urol Oncol2022-11-24T00:00:002022Robotic post-chemotherapy retroperitoneal lymph node dissection for testicular cancer: A multicenter collaborative study.36129376Labbate CV, Klotz L, Morrow M, Cooperberg M, Esserman L, Eggener SEThe Journal of urologyFocal Therapy for Prostate Cancer: Evolutionary Parallels to Breast Cancer Treatment. J Urol. 2023 01; 209(1):49-57.J Urol2022-09-21T00:00:002022Focal Therapy for Prostate Cancer: Evolutionary Parallels to Breast Cancer Treatment.36319552Witmer HDD, Dhiman A, Giurcanu M, Eng OS, Eggener S, Kindler HL, Turaga KKUrologic oncologyA population-based evaluation of tunica vaginalis mesothelioma: An analysis of the National Cancer Database. Urol Oncol. 2023 01; 41(1):52.e11-52.e20.Urol Oncol2022-10-29T00:00:002022A population-based evaluation of tunica vaginalis mesothelioma: An analysis of the National Cancer Database.Authorship 1609371436787661Antonelli L, Ardizzone D, Ravi P, Bagrodia A, Mego M, Daneshmand S, Nicolai N, Nazzani S, Giannatempo P, Franza A, Heidenreich A, Paffenholz P, Saoud R, Eggener S, Ho M, Oswald N, Olson K, Tryakin A, Fedyanin M, Naoun N, Javaud C, Fizazi K, King JM, Adra N, Douglawi A, Cary C, Sweeney C, Fankhauser CDEuropean journal of cancer (Oxford, England : 1990)Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study. Eur J Cancer. 2023 03; 182:144-154.Eur J Cancer2023-01-20T00:00:002023Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study.https://cgh.uchicago.edu/page/leadershipGlobal Healthhttps://www.uchicagomedicine.org/find-a-physician/physician/olufunmilayo-i-olopadeUChicago Medicinehttps://cancerbio.uchicago.edu/program/faculty/olufunmilayo-olopadeCancer Biologyhttps://www.uchicagomedicine.org/conditions-services/cancer/cancer-risk-preventionCancer Risk and Preventionhttps://www.uchicagomedicine.org/find-a-physician/physician/stanley-liauwUCMC Stanley Liauw MDoncostanhttps://www.thedrazergroup.org/Drazer Group WebsiteTwitter michaelwd Solving Mystery of a Rare Blood Cancer Leads to a Cure Solving the Mystery of a Blood Cancer Leads to a CureAuthorship 1619965Authorship 1620167Authorship 1629883Authorship 1619955Authorship 16220515Authorship 1630844Authorship 163124637042807Ho MD, Ross AE, Eggener SEThe Journal of urologyRisk Stratification of Low-risk Prostate Cancer: Individualizing Care in the Era of Active Surveillance. J Urol. 2023 07; 210(1):38-45.J Urol2023-04-12T00:00:002023Risk Stratification of Low-risk Prostate Cancer: Individualizing Care in the Era of Active Surveillance.37096575Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, Fine SW, Han M, Kim SK, Kirkby E, Konety BR, Miner M, Moses K, Nissenberg MG, Pinto PA, Salami SS, Souter L, Thompson IM, Lin DWThe Journal of urologyEarly Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy. J Urol. 2023 07; 210(1):54-63.J Urol2023-04-25T00:00:002023Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy.37096582Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, Fine SW, Han M, Kim SK, Kirkby E, Konety BR, Miner M, Moses K, Nissenberg MG, Pinto PA, Salami SS, Souter L, Thompson IM, Lin DWThe Journal of urologyEarly Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. J Urol. 2023 07; 210(1):46-53.J Urol2023-04-25T00:00:002023Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.37099737Vickers A, Berlin A, Paner G, Cooperberg M, Wolinsky H, Eggener SJCO global oncologyReply to X. Farré et al. JCO Glob Oncol. 2023 Apr; 9:e2300015.JCO Glob Oncol2023-04-01T00:00:002023Reply to X. Farré et al.36913642Daneshmand S, Cary C, Masterson T, Einhorn L, Adra N, Boorjian SA, Kollmannsberger C, Schuckman A, So A, Black P, Bagrodia A, Skinner E, Alemozaffar M, Brand T, Eggener S, Pierorazio P, Stratton K, Nappi L, Nichols C, Luo C, Li M, Hu BJournal of clinical oncology : official journal of the American Society of Clinical OncologySurgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy. J Clin Oncol. 2023 06 01; 41(16):3009-3018.J Clin Oncol2023-03-13T00:00:002023Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy.37072903Paner GP, Zhou M, Simko JP, Eggener SE, van der Kwast TAdvances in anatomic pathologyRenaming Grade Group 1 Prostate "Cancer" From a Pathology Perspective: A Call for Multidisciplinary Discussion. Adv Anat Pathol. 2023 Apr 17.Adv Anat Pathol2023-04-17T00:00:002023Renaming Grade Group 1 Prostate "Cancer" From a Pathology Perspective: A Call for Multidisciplinary Discussion.37117112Saoud R, Woranisarakul V, Paner GP, Ramotar M, Berlin A, Cooperberg M, Eggener SEEuropean urology focusPhysician Perception of Grade Group 1 Prostate Cancer. Eur Urol Focus. 2023 11; 9(6):966-973.Eur Urol Focus2023-04-26T00:00:002023Physician Perception of Grade Group 1 Prostate Cancer.Authorship 16374814Authorship 1640665Authorship 1640421237358605Lee G, Chatterjee A, Harmath C, Karademir I, Engelmann R, Yousuf A, Islam S, Karczmar G, Oto A, Giurcanu M, Antic T, Eggener SAbdominal radiology (New York)Improving reader accuracy and specificity with the addition of hybrid multidimensional-MRI to multiparametric-MRI in diagnosing clinically significant prostate cancers. Abdom Radiol (NY). 2023 10; 48(10):3216-3228.Abdom Radiol (NY)2023-06-26T00:00:002023Improving reader accuracy and specificity with the addition of hybrid multidimensional-MRI to multiparametric-MRI in diagnosing clinically significant prostate cancers.37285311Berlin A, Ramotar M, Santiago AT, Liu Z, Li J, Wolinsky H, Wallis CJD, Chua MLK, Paner GP, van der Kwast T, Cooperberg MR, Vickers AJ, Urbach DR, Eggener SEJournal of the National Cancer InstituteThe influence of the "cancer" label on perceptions and management decisions for low-grade prostate cancer. J Natl Cancer Inst. 2023 11 08; 115(11):1364-1373.J Natl Cancer Inst2023-11-08T00:00:002023The influence of the "cancer" label on perceptions and management decisions for low-grade prostate cancer.37384841Yim K, Ma C, Carlsson S, Lilja H, Mucci L, Penney K, Kibel AS, Eggener S, Preston MAThe Journal of urologyFree PSA and Clinically Significant and Fatal Prostate Cancer in the PLCO Screening Trial. J Urol. 2023 10; 210(4):630-638.J Urol2023-06-29T00:00:002023Free PSA and Clinically Significant and Fatal Prostate Cancer in the PLCO Screening Trial.PathologyRadiologySurgeryUniversity of Chicago28.30660.0075766601research areas3.965360.027631462coauthor of780.51463.362460similar to11339selected publicationsGregoryZagajaGregory Zagaja41.78927490000000-87.601250000000001200Zagaja, GregoryProfessorKathyMangoldKathy Mangold41.78927490000000-87.601250000000001205Mangold, KathyCLINICAL ASSOCIATE PROFESSORStanleyLiauwStanley Liauw41.78927490000000-87.601250000000001228Liauw, StanleyProfessor37592674Murthy P, Malik RD, McCammon KA, Schneck FX, deVries C, Chrouser K, Eggener SEUrology practicePerspectives on International Urological Volunteerism: A Survey of IVUmed Resident Scholar Alumni. Urol Pract. 2017 Mar; 4(2):176-182.Urol Pract2016-10-06T00:00:002016Perspectives on International Urological Volunteerism: A Survey of IVUmed Resident Scholar Alumni.37639675Ho MD, Yeo KJ, Eggener SEAmerican journal of clinical pathologyTime to stop reporting estimates of any prostate cancer risk with percentage of free prostate-specific antigen. Am J Clin Pathol. 2024 Jan 04; 161(1):1-3.Am J Clin Pathol2024-01-04T00:00:002024Time to stop reporting estimates of any prostate cancer risk with percentage of free prostate-specific antigen.37559256Loeb S, Bayne CE, Frey C, Davies BJ, Averch TD, Woo HH, Stork B, Cooperberg MR, Griebling TL, Eggener SE, American Urological Association Social Media Work GroupUrology practiceUpdated Survey of Social Media Use by Members of the American Urological Association. Urol Pract. 2015 May; 2(3):138-143.Urol Pract2015-02-21T00:00:002015Updated Survey of Social Media Use by Members of the American Urological Association.37656935Antonelli L, Ardizzone D, Tachibana I, Adra N, Cary C, Hugar L, Sexton WJ, Bagrodia A, Mego M, Daneshmand S, Nicolai N, Nazzani S, Giannatempo P, Franza A, Heidenreich A, Paffenholz P, Saoud R, Eggener S, Ho M, Oswald N, Olson K, Tryakin A, Fedyanin M, Naoun N, Javaud C, Cazzaniga W, Nicol D, Gerdtsson A, Tandstad T, Fizazi K, Fankhauser CD, EAU-YAU Penile and Testis Cancer Working GroupJournal of clinical oncology : official journal of the American Society of Clinical OncologyRisk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer. J Clin Oncol. 2023 Dec 01; 41(34):5296-5305.J Clin Oncol2023-09-01T00:00:002023Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer.Authorship 16575410Authorship 1658227Authorship 16593418Authorship 1661495AbhinavSidanaAbhinav Sidana41.7886000000000087.598699999999994460Sidana, AbhinavAssociate ProfessorGladell P.PanerGladell P. Paner41.78927490000000-87.60125000000000146Paner, Gladell P.ProfessorAriehShalhavArieh Shalhav41.78927490000000-87.601250000000001625Shalhav, AriehProfessorOlufunmilayoOlopade321vBIF1GuTQkntjbwjr93A=Olufunmilayo Olopade41.78927490000000-87.601250000000001960Olopade, OlufunmilayoProfessorMohan S.GundetiMohan S. Gundeti41.78927490000000-87.601250000000002209Gundeti, Mohan S.ProfessorCarrie W.Rinker-SchaefferCarrie W. Rinker-Schaeffer41.78927490000000-87.601250000000002220Rinker-Schaeffer, Carrie W.ProfessorAytekinOto2HZmK7QWEeXakH1rLkPq5g==Aytekin Oto41.78927490000000-87.601250000000002558Oto, AytekinProfessorAuthorship 1682051137961155Hoffmann TJ, Graff RE, Madduri RK, Rodriguez AA, Cario CL, Feng K, Jiang Y, Wang A, Klein RJ, Pierce BL, Eggener S, Tong L, Blot W, Long J, Rebbeck T, Lachance J, Andrews C, Adebiyi AO, Adusei B, Aisuodionoe-Shadrach OI, Fernandez PW, Jalloh M, Janivara R, Chen WC, Mensah JE, Agalliu I, Berndt SI, Shelley JP, Schaffer K, Machiela MJ, Freedman ND, Huang WY, Li SA, Goodman PJ, Till C, Thompson I, Lilja H, Van Den Eeden SK, Chanock SJ, Mosley JD, Conti DV, Haiman CA, Justice AC, Kachuri L, Witte JSmedRxiv : the preprint server for health sciencesGenome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves cross-ancestry prediction. medRxiv. 2023 Oct 30.medRxiv2023-10-30T00:00:002023Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves cross-ancestry prediction.Authorship 1696665Authorship 1697042338261983Aggarwal R, Heller G, Hillman DW, Xiao H, Picus J, Taplin ME, Dorff T, Appleman L, Weckstein D, Patnaik A, Bryce A, Shevrin D, Mohler J, Anderson D, Rao A, Tagawa S, Tan A, Halabi S, Dooley K, O'Brien P, Chen R, Ryan CJ, Eggener SE, Morris MJ, EORTC-55994 Study GroupJournal of clinical oncology : official journal of the American Society of Clinical OncologyPRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). J Clin Oncol. 2024 Jan 23; JCO2301157.J Clin Oncol2024-01-23T00:00:002024PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).38278665Vickers AJ, Assel M, Cooperberg MR, Fine SW, Eggener SEuropean urologyAmount of Gleason Pattern 3 Is Not Predictive of Risk in Grade Group 2-4 Prostate Cancer. Eur Urol. 2024 Jan 25.Eur Urol2024-01-25T00:00:002024Amount of Gleason Pattern 3 Is Not Predictive of Risk in Grade Group 2-4 Prostate Cancer.Authorship 170641438403108Villota CK, Hou SW, Judge C, Eggener S, Paner G, Raheem OAFertility and sterilityEx-vivo microscopic oncotesticular sperm extraction: step-by-step surgical technique at time of radical orchiectomy. Fertil Steril. 2024 Feb 23.Fertil Steril2024-02-23T00:00:002024Ex-vivo microscopic oncotesticular sperm extraction: step-by-step surgical technique at time of radical orchiectomy.true1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1CLINICAL ASSOCIATE PROFESSORCLINICAL ASSOCIATE PROFESSORtrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessorAuthorship 661911Authorship 652273Authorship 649993Authorship 654004Authorship 653915Authorship 674684Authorship 680741Authorship 675795Authorship 690349Authorship 689624Authorship 699863Authorship 701728Authorship 702671Authorship 703515Authorship 6893820Authorship 693237Authorship 689581Authorship 7168821Authorship 719349Authorship 710895Authorship 724123Authorship 720203Authorship 714895Authorship 741105Authorship 742133Authorship 737325Authorship 741774Authorship 752941Authorship 751784Authorship 768441Authorship 764991Authorship 772487Authorship 781806Authorship 766721Authorship 7695111Authorship 769666Authorship 7780412Authorship 785215Authorship 793645Authorship 714819Authorship 721112Authorship 684382Authorship 767001Authorship 77120325027862Weiner AB, Patel SG, Richards KA, Szmulewitz RZ, Eggener SEProstate cancer and prostatic diseasesPopulation-based analysis of treatment modalities and survival for clinically localized small-cell carcinoma of the prostate. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):286-91.Prostate Cancer Prostatic Dis2014-07-15T00:00:002014Population-based analysis of treatment modalities and survival for clinically localized small-cell carcinoma of the prostate.25087674Eggener SUrologic oncologyCommentary on "African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?" Sundi D, Ross AE, Humphreys EB, Han M, Partin AW, Carter HB, Schaeffer EM, Johns Hopkins University, Baltimore, MD. J Clin Oncol 2013; 31(24):2991-7. [Epub 2013 Jun 17]. doi: 10.1200/JCO.2012.47.0302. Urol Oncol. 2014 Aug; 32(6):936.Urol Oncol2014-08-01T00:00:002014Commentary on "African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?" Sundi D, Ross AE, Humphreys EB, Han M, Partin AW, Carter HB, Schaeffer EM, Johns Hopkins University, Baltimore, MD. J Clin Oncol 2013; 31(24):2991-7. [Epub 2013 Jun 17]. doi: 10.1200/JCO.2012.47.0302.25030752Nigam M, Aschebrook-Kilfoy B, Shikanov S, Eggener SWorld journal of urologyIncreasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol. 2015 May; 33(5):623-31.World J Urol2014-07-17T00:00:002014Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009.25044254Cohen A, Richards KA, Patel S, Weiner A, Eggener SE, Szmulewitz RZUrologic oncologyMetastatic small cell carcinoma of the prostate: Population-based analysis of patient characteristics and treatment paradigms. Urol Oncol. 2015 Feb; 33(2):70.e1-7.Urol Oncol2014-07-16T00:00:002014Metastatic small cell carcinoma of the prostate: Population-based analysis of patient characteristics and treatment paradigms.25017694Hu JC, Williams SB, Carter SC, Eggener SE, Prasad S, Chamie K, Trinh QD, Sun M, Nguyen PL, Lipsitz SRUrologic oncologyPopulation-based assessment of prostate-specific antigen testing for prostate cancer in the elderly. Urol Oncol. 2015 Feb; 33(2):69.e29-34.Urol Oncol2014-07-10T00:00:002014Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly.25087672Eggener SUrologic oncologyCommentary on "Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare." Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM, Department of Urology, New York University, New York, NY. J Urol 2013; 189(3):867-70. [Epub 2012 Oct 9]. doi: 10.1016/j.juro.2012.10.005. Urol Oncol. 2014 Aug; 32(6):935-6.Urol Oncol2014-08-01T00:00:002014Commentary on "Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare." Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM, Department of Urology, New York University, New York, NY. J Urol 2013; 189(3):867-70. [Epub 2012 Oct 9]. doi: 10.1016/j.juro.2012.10.005.25087673Eggener SUrologic oncologyCommentary on "Intermittent versus continuous androgen deprivation in prostate cancer." Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr, University of Michigan, Division of Hematology/Oncology, Ann Arbor, MI. N Engl J Med 2013; 368(14):1314-25. doi: 10.1056/NEJMoa1212299. Urol Oncol. 2014 Aug; 32(6):936-7.Urol Oncol2014-08-01T00:00:002014Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr, University of Michigan, Division of Hematology/Oncology, Ann Arbor, MI. N Engl J Med 2013; 368(14):1314-25. doi: 10.1056/NEJMoa1212299.25106900Weiner AB, Patel SG, Etzioni R, Eggener SEThe Journal of urologyNational trends in the management of low and intermediate risk prostate cancer in the United States. J Urol. 2015 Jan; 193(1):95-102.J Urol2014-08-05T00:00:002014National trends in the management of low and intermediate risk prostate cancer in the United States.23537686Moore CM, Kasivisvanathan V, Eggener S, Emberton M, Fütterer JJ, Gill IS, Grubb Iii RL, Hadaschik B, Klotz L, Margolis DJ, Marks LS, Melamed J, Oto A, Palmer SL, Pinto P, Puech P, Punwani S, Rosenkrantz AB, Schoots IG, Simon R, Taneja SS, Turkbey B, Ukimura O, van der Meulen J, Villers A, Watanabe Y, START ConsortiumEuropean urologyStandards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol. 2013 Oct; 64(4):544-52.Eur Urol2013-03-20T00:00:002013Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group.25312551Bachrach L, Negron E, Liu JS, Su YK, Paparello JJ, Eggener S, Kundu SDUrologyPreoperative nuclear renal scan underestimates renal function after radical nephrectomy. Urology. 2014 Dec; 84(6):1402-6.Urology2014-10-12T00:00:002014Preoperative nuclear renal scan underestimates renal function after radical nephrectomy.23907555Pearce S, Steinberg Z, Eggener SCurrent urology reportsCritical evaluation of modified templates and current trends in retroperitoneal lymph node dissection. Curr Urol Rep. 2013 Oct; 14(5):511-7.Curr Urol Rep2013-10-01T00:00:002013Critical evaluation of modified templates and current trends in retroperitoneal lymph node dissection.25708953Pearce SM, Richards KA, Patel SG, Pariser JJ, Eggener SEUrologic oncologyPopulation-based analysis of salvage radical prostatectomy with examination of factors associated with adverse perioperative outcomes. Urol Oncol. 2015 Apr; 33(4):163.e1-6.Urol Oncol2015-02-21T00:00:002015Population-based analysis of salvage radical prostatectomy with examination of factors associated with adverse perioperative outcomes.23721959Yuh B, Artibani W, Heidenreich A, Kimm S, Menon M, Novara G, Tewari A, Touijer K, Wilson T, Zorn KC, Eggener SEEuropean urologyThe role of robot-assisted radical prostatectomy and pelvic lymph node dissection in the management of high-risk prostate cancer: a systematic review. Eur Urol. 2014 May; 65(5):918-27.Eur Urol2013-05-18T00:00:002013The role of robot-assisted radical prostatectomy and pelvic lymph node dissection in the management of high-risk prostate cancer: a systematic review.25281389Donaldson IA, Alonzi R, Barratt D, Barret E, Berge V, Bott S, Bottomley D, Eggener S, Ehdaie B, Emberton M, Hindley R, Leslie T, Miners A, McCartan N, Moore CM, Pinto P, Polascik TJ, Simmons L, van der Meulen J, Villers A, Willis S, Ahmed HUEuropean urologyFocal therapy: patients, interventions, and outcomes--a report from a consensus meeting. Eur Urol. 2015 Apr; 67(4):771-7.Eur Urol2014-10-01T00:00:002014Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting.23890317Eggener SE, Large MC, Gerber GS, Pettus J, Yossepowitch O, Smith ND, Kundu S, Kunnavakkam R, Zorn K, Raman JDBJU internationalEmpiric antibiotics for an elevated prostate-specific antigen (PSA) level: a randomised, prospective, controlled multi-institutional trial. BJU Int. 2013 Nov; 112(7):925-9.BJU Int2013-07-26T00:00:002013Empiric antibiotics for an elevated prostate-specific antigen (PSA) level: a randomised, prospective, controlled multi-institutional trial.25542823Leir SH, Browne JA, Eggener SE, Harris AFertility and sterilityCharacterization of primary cultures of adult human epididymis epithelial cells. Fertil Steril. 2015 Mar; 103(3):647-54.e1.Fertil Steril2014-12-24T00:00:002014Characterization of primary cultures of adult human epididymis epithelial cells.25624093Weiner AB, Patel SG, Eggener SEUrologic oncologyPathologic outcomes for low-risk prostate cancer after delayed radical prostatectomy in the United States. Urol Oncol. 2015 Apr; 33(4):164.e11-7.Urol Oncol2015-01-23T00:00:002015Pathologic outcomes for low-risk prostate cancer after delayed radical prostatectomy in the United States.24006289Truong M, Slezak JA, Lin CP, Iremashvili V, Sado M, Razmaria AA, Leverson G, Soloway MS, Eggener SE, Abel EJ, Downs TM, Jarrard DFCancerDevelopment and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer. 2013 Nov 15; 119(22):3992-4002.Cancer2013-09-04T00:00:002013Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer.24006926Patel A, Golan S, Razmaria A, Prasad S, Eggener S, Shalhav ABJU internationalEarly discharge after laparoscopic or robotic partial nephrectomy: care pathway evaluation. BJU Int. 2014 Apr; 113(4):592-7.BJU Int2013-09-05T00:00:002013Early discharge after laparoscopic or robotic partial nephrectomy: care pathway evaluation.25632850Weiner AB, Murthy P, Richards KA, Patel SG, Eggener SEThe Journal of urologyPopulation based analysis of incidence and predictors of open conversion during minimally invasive radical prostatectomy. J Urol. 2015 Mar; 193(3):826-31.J Urol2015-01-26T00:00:002015Population based analysis of incidence and predictors of open conversion during minimally invasive radical prostatectomy.24035631Stephenson AJ, Eggener SE, Hernandez AV, Klein EA, Kattan MW, Wood DP, Rabah DM, Eastham JA, Scardino PTEuropean urologyDo margins matter? The influence of positive surgical margins on prostate cancer-specific mortality. Eur Urol. 2014 Apr; 65(4):675-80.Eur Urol2013-08-27T00:00:002013Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality.24033335Golan S, Patel AR, Eggener SE, Shalhav ALJournal of endourologyThe volume of nonneoplastic parenchyma in a minimally invasive partial nephrectomy specimen: predictive factors and impact on renal function. J Endourol. 2014 Feb; 28(2):196-200.J Endourol2013-11-04T00:00:002013The volume of nonneoplastic parenchyma in a minimally invasive partial nephrectomy specimen: predictive factors and impact on renal function.24123318Hansford BG, Peng Y, Jiang Y, Al-Ahmadie H, Eggener S, Yousuf A, Oto AJournal of magnetic resonance imaging : JMRIRevisiting the central gland anatomy via MRI: does the central gland extend below the level of verumontanum? J Magn Reson Imaging. 2014 Jan; 39(1):167-71.J Magn Reson Imaging2013-10-02T00:00:002013Revisiting the central gland anatomy via MRI: does the central gland extend below the level of verumontanum?24147475Karademir I, Shen D, Peng Y, Liao S, Jiang Y, Yousuf A, Karczmar G, Sammet S, Wang S, Medved M, Antic T, Eggener S, Oto AAJR. American journal of roentgenologyProstate volumes derived from MRI and volume-adjusted serum prostate-specific antigen: correlation with Gleason score of prostate cancer. AJR Am J Roentgenol. 2013 Nov; 201(5):1041-8.AJR Am J Roentgenol2013-11-01T00:00:002013Prostate volumes derived from MRI and volume-adjusted serum prostate-specific antigen: correlation with Gleason score of prostate cancer.24274744Loeb S, Bayne CE, Frey C, Davies BJ, Averch TD, Woo HH, Stork B, Cooperberg MR, Eggener SE, American Urological Association Social Media Work GroupBJU internationalUse of social media in urology: data from the American Urological Association (AUA). BJU Int. 2014 Jun; 113(6):993-8.BJU Int2014-06-01T00:00:002014Use of social media in urology: data from the American Urological Association (AUA).24523016Drazer MW, Prasad SM, Huo D, Schonberg MA, Dale W, Szmulewitz RZ, Eggener SECancerNational trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making. Cancer. 2014 May 15; 120(10):1491-8.Cancer2014-02-12T00:00:002014National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.24674317Corbin KS, Kunnavakkam R, Eggener SE, Liauw SLPractical radiation oncologyIntensity modulated radiation therapy after radical prostatectomy: Early results show no decline in urinary continence, gastrointestinal, or sexual quality of life. Pract Radiat Oncol. 2013 Apr-Jun; 3(2):138-44.Pract Radiat Oncol2012-06-13T00:00:002012Intensity modulated radiation therapy after radical prostatectomy: Early results show no decline in urinary continence, gastrointestinal, or sexual quality of life.24555621Peng Y, Jiang Y, Antic T, Sethi I, Schmid-Tannwald C, Eggener S, Oto AAJR. American journal of roentgenologyApparent diffusion coefficient for prostate cancer imaging: impact of B values. AJR Am J Roentgenol. 2014 Mar; 202(3):W247-53.AJR Am J Roentgenol2014-03-01T00:00:002014Apparent diffusion coefficient for prostate cancer imaging: impact of B values.24533870Peng Y, Jiang Y, Antic T, Giger ML, Eggener SE, Oto ARadiologyValidation of quantitative analysis of multiparametric prostate MR images for prostate cancer detection and aggressiveness assessment: a cross-imager study. Radiology. 2014 May; 271(2):461-71.Radiology2014-02-12T00:00:002014Validation of quantitative analysis of multiparametric prostate MR images for prostate cancer detection and aggressiveness assessment: a cross-imager study.24444476van den Bos W, Muller BG, Ahmed H, Bangma CH, Barret E, Crouzet S, Eggener SE, Gill IS, Joniau S, Kovacs G, Pahernik S, de la Rosette JJ, Rouvière O, Salomon G, Ward JF, Scardino PTEuropean urologyFocal therapy in prostate cancer: international multidisciplinary consensus on trial design. Eur Urol. 2014 Jun; 65(6):1078-83.Eur Urol2014-01-13T00:00:002014Focal therapy in prostate cancer: international multidisciplinary consensus on trial design.24703469Hansford BG, Karademir I, Peng Y, Jiang Y, Karczmar G, Thomas S, Yousuf A, Antic T, Eggener S, Oto AAcademic radiologyDynamic contrast-enhanced MR imaging features of the normal central zone of the prostate. Acad Radiol. 2014 May; 21(5):569-77.Acad Radiol2014-05-01T00:00:002014Dynamic contrast-enhanced MR imaging features of the normal central zone of the prostate.24767688Eggener SUrologic oncologyCommentary on: "Long-term functional outcomes after treatment for localized prostate cancer." Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF. Department of Urologic Surgery and the Center for Surgical Quality and Outcomes Research, Vanderbilt University, Nashville, TN.: N Engl J Med 2013;368(5):436-45. doi: 10.1056/NEJMoa1209978. Urol Oncol. 2014 May; 32(4):513-4.Urol Oncol2014-05-01T00:00:002014Commentary on: "Long-term functional outcomes after treatment for localized prostate cancer." Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF. Department of Urologic Surgery and the Center for Surgical Quality and Outcomes Research, Vanderbilt University, Nashville, TN.: N Engl J Med 2013;368(5):436-45. doi: 10.1056/NEJMoa1209978.24629082Eggener SBJU internationalElastographic search for the (high-grade) tree in the (prostatic) forest. BJU Int. 2014 Apr; 113(4):514-5.BJU Int2014-04-01T00:00:002014Elastographic search for the (high-grade) tree in the (prostatic) forest.24630416Weiner AB, Etzioni R, Eggener SEEuropean urologyOngoing Gleason grade migration in localized prostate cancer and implications for use of active surveillance. Eur Urol. 2014 Oct; 66(4):611-2.Eur Urol2014-03-04T00:00:002014Ongoing Gleason grade migration in localized prostate cancer and implications for use of active surveillance.24625427Wenger H, Yousuf A, Oto A, Eggener SCurrent opinion in urologyLaser ablation as focal therapy for prostate cancer. Curr Opin Urol. 2014 May; 24(3):236-40.Curr Opin Urol2014-05-01T00:00:002014Laser ablation as focal therapy for prostate cancer.24935823Richards KA, Negron E, Cohn JA, Steinberg Z, Eggener SE, Shalhav ALJournal of endourologyThe impact of body mass index on renal functional outcomes following minimally invasive partial nephrectomy. J Endourol. 2014 Nov; 28(11):1338-44.J Endourol2014-08-21T00:00:002014The impact of body mass index on renal functional outcomes following minimally invasive partial nephrectomy.24965212Valerio M, Emberton M, Barret E, Eberli D, Eggener SE, Ehdaie B, Jichlinski P, Ward JF, Ahmed HUExpert review of anticancer therapyHealth technology assessment in evolution - focal therapy in localised prostate cancer. Expert Rev Anticancer Ther. 2014 Nov; 14(11):1359-67.Expert Rev Anticancer Ther2014-06-25T00:00:002014Health technology assessment in evolution - focal therapy in localised prostate cancer.24703979Eggener SThe Journal of urologyEditorial comment. J Urol. 2014 Jul; 192(1):81.J Urol2014-04-01T00:00:002014Editorial comment.24757509Smid MC, Bhardwaj NR, Di Giovanni LM, Eggener S, Torre MDInfectious disease reportsRenal hemorrhagic actinomycotic abscess in pregnancy. Infect Dis Rep. 2014 Feb 18; 6(1):5157.Infect Dis Rep2014-02-14T00:00:002014Renal hemorrhagic actinomycotic abscess in pregnancy.23242033Cosentino M, Breda A, Sanguedolce F, Landman J, Stolzenburg JU, Verze P, Rassweiler J, Van Poppel H, Klingler HC, Janetschek G, Celia A, Kim FJ, Thalmann G, Nagele U, Mogorovich A, Bolenz C, Knoll T, Porpiglia F, Alvarez-Maestro M, Francesca F, Deho F, Eggener S, Abbou C, Meng MV, Aron M, Laguna P, Mladenov D, D'Addessi A, Bove P, Schiavina R, De Cobelli O, Merseburger AS, Dalpiaz O, D'Ancona FC, Polascik TJ, Muschter R, Leppert TJ, Villavicencio HWorld journal of urologyThe use of mannitol in partial and live donor nephrectomy: an international survey. World J Urol. 2013 Aug; 31(4):977-82.World J Urol2012-12-15T00:00:002012The use of mannitol in partial and live donor nephrectomy: an international survey.24817142Eggener SE, Clark MA, Shikanov S, Smith B, Kaag M, Russo P, Wheat JC, Wolf JS, Matin SF, Huang WC, Harel M, Cambio J, Shalhav AL, Raman JDWorld journal of urologyImpact of warm versus cold ischemia on renal function following partial nephrectomy. World J Urol. 2015 Mar; 33(3):351-7.World J Urol2014-05-10T00:00:002014Impact of warm versus cold ischemia on renal function following partial nephrectomy.25604714Eggener SBJU internationalHow active should active surveillance be? BJU Int. 2015 Feb; 115(2):176-7.BJU Int2015-02-01T00:00:002015How active should active surveillance be?25002728Prasad SM, Eggener SE, Lipsitz SR, Irwin MR, Ganz PA, Hu JCJournal of clinical oncology : official journal of the American Society of Clinical OncologyEffect of depression on diagnosis, treatment, and mortality of men with clinically localized prostate cancer. J Clin Oncol. 2014 Aug 10; 32(23):2471-8.J Clin Oncol2014-07-07T00:00:002014Effect of depression on diagnosis, treatment, and mortality of men with clinically localized prostate cancer.Authorship 79526725734923Sampat A, Parakati I, Kunnavakkam R, Glick DB, Lee NK, Tenney M, Eggener S, Roth SAnesthesiologyCorneal abrasion in hysterectomy and prostatectomy: role of laparoscopic and robotic assistance. Anesthesiology. 2015 May; 122(5):994-1001.Anesthesiology2015-05-01T00:00:002015Corneal abrasion in hysterectomy and prostatectomy: role of laparoscopic and robotic assistance.Authorship 79602326019967Gabr AH, Steinberg Z, Eggener SE, Stuart Wolf JArab journal of urologyIndications for adrenalectomy during radical nephrectomy for renal cancer. Arab J Urol. 2014 Dec; 12(4):304-8.Arab J Urol2014-10-22T00:00:002014Indications for adrenalectomy during radical nephrectomy for renal cancer.1010Chicago60637ILAuthorship 80680526172350Baad M, Ericson K, Yassan L, Oto A, Eggener S, Nottingham CU, Richards KA, Thomas SRadiographics : a review publication of the Radiological Society of North America, IncGiant Multilocular Cystadenoma of the Prostate. Radiographics. 2015 Jul-Aug; 35(4):1051-5.Radiographics2015-07-01T00:00:002015Giant Multilocular Cystadenoma of the Prostate.Authorship 80937326216816Pearce SM, Liauw SL, Eggener SEThe Urologic clinics of North AmericaManagement of Low-Stage Testicular Seminoma. Urol Clin North Am. 2015 Aug; 42(3):287-98.Urol Clin North Am2015-06-06T00:00:002015Management of Low-Stage Testicular Seminoma.Authorship 81000326056181Drazer MW, Huo D, Eggener SEJournal of clinical oncology : official journal of the American Society of Clinical OncologyNational Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening. J Clin Oncol. 2015 Aug 01; 33(22):2416-23.J Clin Oncol2015-06-08T00:00:002015National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.Authorship 81277125849602Eggener SE, Badani K, Barocas DA, Barrisford GW, Cheng JS, Chin AI, Corcoran A, Epstein JI, George AK, Gupta GN, Hayn MH, Kauffman EC, Lane B, Liss MA, Mirza M, Morgan TM, Moses K, Nepple KG, Preston MA, Rais-Bahrami S, Resnick MJ, Siddiqui MM, Silberstein J, Singer EA, Sonn GA, Sprenkle P, Stratton KL, Taylor J, Tomaszewski J, Tollefson M, Vickers A, White WM, Lowrance WTThe Journal of urologyGleason 6 Prostate Cancer: Translating Biology into Population Health. J Urol. 2015 Sep; 194(3):626-34.J Urol2015-04-04T00:00:002015Gleason 6 Prostate Cancer: Translating Biology into Population Health.Authorship 81418126305653Eggener SE, Cifu AS, Nabhan CJAMAProstate Cancer Screening. JAMA. 2015 Aug 25; 314(8):825-6.JAMA2015-08-25T00:00:002015Prostate Cancer Screening.Surgery-UrologyAuthorship 83119926196240Packiam VT, Patel SG, Pariser JJ, Richards KA, Weiner AB, Paner GP, VanderWeele DJ, Zagaja GP, Eggener SEUrologyContemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate. Urology. 2015 Oct; 86(4):777-82.Urology2015-07-18T00:00:002015Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate.Authorship 842445Authorship 84253225701128Ledezma RA, Negron E, Razmaria AA, Dangle P, Eggener SE, Shalhav AL, Zagaja GPWorld journal of urologyRobotic-assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes. World J Urol. 2015 Nov; 33(11):1689-94.World J Urol2015-02-21T00:00:002015Robotic-assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes.26112488Ward JF, Eggener SEAsian journal of andrologyActive surveillance monitoring: the role of novel biomarkers and imaging. Asian J Androl. 2015 Nov-Dec; 17(6):882-4; discussion 883.Asian J Androl2015-11-01T00:00:002015Active surveillance monitoring: the role of novel biomarkers and imaging.Authorship 84396225913390Boström PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, Cooperberg MREuropean urologyGenomic Predictors of Outcome in Prostate Cancer. Eur Urol. 2015 Dec; 68(6):1033-44.Eur Urol2015-04-23T00:00:002015Genomic Predictors of Outcome in Prostate Cancer.Authorship 866933Authorship 872775Authorship 866504Authorship 862653Authorship 86505226666364Valerio M, Emberton M, Eggener SE, Ahmed HUNature reviews. UrologyThe challenging landscape of medical device approval in localized prostate cancer. Nat Rev Urol. 2016 Feb; 13(2):91-8.Nat Rev Urol2015-12-15T00:00:002015The challenging landscape of medical device approval in localized prostate cancer.26808453Browne JA, Yang R, Eggener SE, Leir SH, Harris AMolecular and cellular endocrinologyHNF1 regulates critical processes in the human epididymis epithelium. Mol Cell Endocrinol. 2016 Apr 15; 425:94-102.Mol Cell Endocrinol2016-01-22T00:00:002016HNF1 regulates critical processes in the human epididymis epithelium.25884106Golan S, Eggener SJournal of endourologyEVALUATING THE EMERGING TRENDS IN THE DIAGNOSIS AND TREATMENT OF KIDNEY CANCER—THE RENAL MASS GLOBAL STUDY. J Endourol. 2015 May; 29(5):495-7.J Endourol2015-04-17T00:00:002015EVALUATING THE EMERGING TRENDS IN THE DIAGNOSIS AND TREATMENT OF KIDNEY CANCER—THE RENAL MASS GLOBAL STUDY.26045402Pearce SM, Pariser JJ, Patel SG, Anderson BB, Eggener SE, Zagaja GPWorld journal of urologyThe impact of days off between cases on perioperative outcomes for robotic-assisted laparoscopic prostatectomy. World J Urol. 2016 Feb; 34(2):269-74.World J Urol2015-06-05T00:00:002015The impact of days off between cases on perioperative outcomes for robotic-assisted laparoscopic prostatectomy.26612782Browne JA, Yang R, Leir SH, Eggener SE, Harris AMolecular human reproductionExpression profiles of human epididymis epithelial cells reveal the functional diversity of caput, corpus and cauda regions. Mol Hum Reprod. 2016 Feb; 22(2):69-82.Mol Hum Reprod2015-11-26T00:00:002015Expression profiles of human epididymis epithelial cells reveal the functional diversity of caput, corpus and cauda regions.Authorship 891411626407582Ledezma RA, Negron E, Paner GP, Rjepaj C, Lascano D, Haseebuddin M, Dangle P, Shalhav AL, Crist H, Raman JD, Joel DeCastro G, Harik L, Paroder M, Uzzo RG, Kutikov A, Eggener SEWorld journal of urologyClinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery. World J Urol. 2016 May; 34(5):687-93.World J Urol2015-09-25T00:00:002015Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery.Authorship 89644226389787Golan S, Eggener S, Subotic S, Barret E, Cormio L, Naito S, Tefekli A, Pilar Laguna Pes MBJU internationalPrediction of renal mass aggressiveness using clinical and radiographic features: a global, multicentre prospective study. BJU Int. 2016 06; 117(6):914-22.BJU Int2015-10-25T00:00:002015Prediction of renal mass aggressiveness using clinical and radiographic features: a global, multicentre prospective study.Authorship 898913Authorship 89894226707507Weiner AB, Conti RM, Eggener SEThe Journal of urologyNational Economic Conditions and Patient Insurance Status Predict Prostate Cancer Diagnosis Rates and Management Decisions. J Urol. 2016 May; 195(5):1383-1389.J Urol2015-12-18T00:00:002015National Economic Conditions and Patient Insurance Status Predict Prostate Cancer Diagnosis Rates and Management Decisions.27182910Drazer MW, Eggener SEAnnals of internal medicinePatient-Initiated Prostate Cancer Screening Among Older U.S. Men. Ann Intern Med. 2016 05 17; 164(10):702-3.Ann Intern Med2016-05-17T00:00:002016Patient-Initiated Prostate Cancer Screening Among Older U.S. Men.Authorship 90842126382084Eggener SEuropean urologyProstate Cancer Screening Biomarkers: An Emerging Embarrassment of 'Riches'? Eur Urol. 2016 07; 70(1):54-55.Eur Urol2015-09-15T00:00:002015Prostate Cancer Screening Biomarkers: An Emerging Embarrassment of 'Riches'?Authorship 91124526860793Pearce SM, Pariser JJ, Karrison T, Patel SG, Eggener SEThe Journal of urologyComparison of Perioperative and Early Oncologic Outcomes between Open and Robotic Assisted Laparoscopic Prostatectomy in a Contemporary Population Based Cohort. J Urol. 2016 07; 196(1):76-81.J Urol2016-02-06T00:00:002016Comparison of Perioperative and Early Oncologic Outcomes between Open and Robotic Assisted Laparoscopic Prostatectomy in a Contemporary Population Based Cohort.Authorship 936056Authorship 93794626961716Son CH, Melotek JM, Liao C, Hubert G, Pelizzari CA, Eggener SE, Liauw SLPractical radiation oncologyBladder dose-volume parameters are associated with urinary incontinence after postoperative intensity modulated radiation therapy for prostate cancer. Pract Radiat Oncol. 2016 Sep-Oct; 6(5):e179-e185.Pract Radiat Oncol2015-12-19T00:00:002015Bladder dose-volume parameters are associated with urinary incontinence after postoperative intensity modulated radiation therapy for prostate cancer.27338841Packiam VT, Nottingham CU, Cohen AJ, Pearce SM, Shalhav AL, Eggener SEJournal of endourologyThe Impact of Perioperative Aspirin on Bleeding Complications Following Robotic Partial Nephrectomy. J Endourol. 2016 09; 30(9):997-1003.J Endourol2016-07-15T00:00:002016The Impact of Perioperative Aspirin on Bleeding Complications Following Robotic Partial Nephrectomy.Authorship 938494Authorship 93817527379821Choy B, Pearce SM, Anderson BB, Shalhav AL, Zagaja G, Eggener SE, Paner GPThe American journal of surgical pathologyPrognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy. Am J Surg Pathol. 2016 10; 40(10):1400-6.Am J Surg Pathol2016-10-01T00:00:002016Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy.27628452Jayram G, Msezane LE, Angelos P, Eggener SEJournal of robotic surgeryRobotic-assisted partial cystectomy for recurrent extra-adrenal pheochromocytoma. J Robot Surg. 2009 Mar; 3(1):41-3.J Robot Surg2009-01-27T00:00:002009Robotic-assisted partial cystectomy for recurrent extra-adrenal pheochromocytoma.Authorship 949781126892160Postema AW, De Reijke TM, Ukimura O, Van den Bos W, Azzouzi AR, Barret E, Baumunk D, Blana A, Bossi A, Brausi M, Coleman JA, Crouzet S, Dominguez-Escrig J, Eggener S, Ganzer R, Ghai S, Gill IS, Gupta RT, Henkel TO, Hohenfellner M, Jones JS, Kahmann F, Kastner C, Köhrmann KU, Kovacs G, Miano R, van Moorselaar RJ, Mottet N, Osorio L, Pieters BR, Polascik TJ, Rastinehad AR, Salomon G, Sanchez-Salas R, Schostak M, Sentker L, Tay KJ, Varkarakis IM, Villers A, Walz J, De la Rosette JJWorld journal of urologyStandardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project. World J Urol. 2016 Oct; 34(10):1373-82.World J Urol2016-02-18T00:00:002016Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project.Authorship 5941610Authorship 608541Authorship 614739Authorship 616448Authorship 600163Authorship 611603Authorship 616487Authorship 600478Authorship 61989223440319Oto A, Sethi I, Karczmar G, McNichols R, Ivancevic MK, Stadler WM, Watson S, Eggener SRadiologyMR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology. 2013 Jun; 267(3):932-40.Radiology2013-02-25T00:00:002013MR imaging-guided focal laser ablation for prostate cancer: phase I trial.23440325Soylu FN, Peng Y, Jiang Y, Wang S, Schmid-Tannwald C, Sethi I, Eggener S, Antic T, Oto ARadiologySeminal vesicle invasion in prostate cancer: evaluation by using multiparametric endorectal MR imaging. Radiology. 2013 Jun; 267(3):797-806.Radiology2013-02-25T00:00:002013Seminal vesicle invasion in prostate cancer: evaluation by using multiparametric endorectal MR imaging.21906967Messer JC, Terrell JD, Herman MP, Ng CK, Scherr DS, Scoll B, Boorjian SA, Uzzo RG, Wille M, Eggener SE, Lucas SM, Lotan Y, Shariat SF, Raman JDUrologic oncologyMulti-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. Urol Oncol. 2013 Aug; 31(6):904-8.Urol Oncol2011-09-09T00:00:002011Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma.23313207Lane BR, Golan S, Eggener S, Tobert CM, Kahnoski RJ, Kutikov A, Smaldone M, Whelan CM, Shalhav A, Uzzo RGThe Journal of urologyDifferential use of partial nephrectomy for intermediate and high complexity tumors may explain variability in reported utilization rates. J Urol. 2013 Jun; 189(6):2047-53.J Urol2013-01-09T00:00:002013Differential use of partial nephrectomy for intermediate and high complexity tumors may explain variability in reported utilization rates.22717242Liauw SL, Pitroda SP, Eggener SE, Stadler WM, Pelizzari CA, Vannier MW, Oto AInternational journal of radiation oncology, biology, physicsEvaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):378-84.Int J Radiat Oncol Biol Phys2012-06-18T00:00:002012Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging.23234624Eggener SE, Mueller A, Berglund RK, Ayyathurai R, Soloway C, Soloway MS, Abouassaly R, Klein EA, Jones SJ, Zappavigna C, Goldenberg L, Scardino PT, Eastham JA, Guillonneau BThe Journal of urologyA multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol. 2013 Jan; 189(1 Suppl):S19-25; discussion S25.J Urol2013-01-01T00:00:002013A multi-institutional evaluation of active surveillance for low risk prostate cancer.23541252Richards K, Eggener SEuropean urologyWords of wisdom: Re: Do adenocarcinomas of the prostate with Gleason Score (GS) = 6 have the potential to metastasize to lymph nodes? Eur Urol. 2013 May; 63(5):960.Eur Urol2013-05-01T00:00:002013Words of wisdom: Re: Do adenocarcinomas of the prostate with Gleason Score (GS) = 6 have the potential to metastasize to lymph nodes?22759270Shikanov S, Marchetti P, Desai V, Razmaria A, Antic T, Al-Ahmadie H, Zagaja G, Eggener S, Brendler C, Shalhav ABJU internationalShort (= 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy. BJU Int. 2013 Apr; 111(4):559-63.BJU Int2012-07-03T00:00:002012Short (= 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy.23392430Peng Y, Jiang Y, Yang C, Brown JB, Antic T, Sethi I, Schmid-Tannwald C, Giger ML, Eggener SE, Oto ARadiologyQuantitative analysis of multiparametric prostate MR images: differentiation between prostate cancer and normal tissue and correlation with Gleason score--a computer-aided diagnosis development study. Radiology. 2013 Jun; 267(3):787-96.Radiology2013-02-07T00:00:002013Quantitative analysis of multiparametric prostate MR images: differentiation between prostate cancer and normal tissue and correlation with Gleason score--a computer-aided diagnosis development study.Authorship 958311Authorship 957581Authorship 958655Authorship 962051Authorship 96149527613117Eggener SEThe Journal of urologyEditorial Comment. J Urol. 2016 12; 196(6):1668-1669.J Urol2016-09-06T00:00:002016Editorial Comment.27743755Eggener SEuropean urologyGeneralizability of Clinical Trials: Why It Matters for Patients and Public Policy. Eur Urol. 2017 04; 71(4):515-516.Eur Urol2016-10-12T00:00:002016Generalizability of Clinical Trials: Why It Matters for Patients and Public Policy.27692833Wenger H, Weiner AB, Razmaria A, Paner GP, Eggener SEUrologic oncologyRisk of lymph node metastases in pathological gleason score=6 prostate adenocarcinoma: Analysis of institutional and population-based databases. Urol Oncol. 2017 01; 35(1):31.e1-31.e6.Urol Oncol2016-09-28T00:00:002016Risk of lymph node metastases in pathological gleason score=6 prostate adenocarcinoma: Analysis of institutional and population-based databases.27449263Eggener SE, Yousuf A, Watson S, Wang S, Oto AThe Journal of urologyPhase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer. J Urol. 2016 12; 196(6):1670-1675.J Urol2016-07-20T00:00:002016Phase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer.27320841Rosenkrantz AB, Verma S, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K, Haider MA, Margolis DJ, Marks LS, Pinto P, Sonn GA, Taneja SSThe Journal of urologyProstate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. J Urol. 2016 12; 196(6):1613-1618.J Urol2016-06-16T00:00:002016Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR.Authorship 96267327431496Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EMProstate cancer and prostatic diseasesIncreasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis. 2016 12; 19(4):395-397.Prostate Cancer Prostatic Dis2016-07-19T00:00:002016Increasing incidence of metastatic prostate cancer in the United States (2004-2013).Authorship 9774310Authorship 977463Authorship 97773627663460Wymer KM, Pearce SM, Harris KT, Pierorazio PM, Daneshmand S, Eggener SEThe Journal of urologyAdherence to National Comprehensive Cancer Network® Guidelines for Testicular Cancer. J Urol. 2017 03; 197(3 Pt 1):684-689.J Urol2016-09-20T00:00:002016Adherence to National Comprehensive Cancer Network® Guidelines for Testicular Cancer.27595377Valerio M, Cerantola Y, Eggener SE, Lepor H, Polascik TJ, Villers A, Emberton MEuropean urologyNew and Established Technology in Focal Ablation of the Prostate: A Systematic Review. Eur Urol. 2017 01; 71(1):17-34.Eur Urol2016-08-29T00:00:002016New and Established Technology in Focal Ablation of the Prostate: A Systematic Review.27986368Anderson BB, Oberlin DT, Razmaria AA, Choy B, Zagaja GP, Shalhav AL, Meeks JJ, Yang XJ, Paner GP, Eggener SEEuropean urologyExtraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer. Eur Urol. 2017 09; 72(3):455-460.Eur Urol2016-12-13T00:00:002016Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer.Authorship 992171Authorship 99224327626903Weiner AB, Pearce SM, Eggener SECancerManagement trends for men with early-stage nonseminomatous germ cell tumors of the testicle: An analysis of the National Cancer Database. Cancer. 2017 01 01; 123(2):245-252.Cancer2016-09-14T00:00:002016Management trends for men with early-stage nonseminomatous germ cell tumors of the testicle: An analysis of the National Cancer Database.28065298Eggener S, Salomon G, Scardino PT, De la Rosette J, Polascik TJ, Brewster SEuropean urologyCorrigendum to "Focal Therapy for Prostate Cancer: Possibilities and Limitations" [Eur Urol 2010;58:57-64]. Eur Urol. 2010 Oct; 58(4):644.Eur Urol2010-07-09T00:00:002010Corrigendum to "Focal Therapy for Prostate Cancer: Possibilities and Limitations" [Eur Urol 2010;58:57-64].Authorship 99309528095147Finelli A, Ismaila N, Bro B, Durack J, Eggener S, Evans A, Gill I, Graham D, Huang W, Jewett MA, Latcha S, Lowrance W, Rosner M, Shayegan B, Thompson RH, Uzzo R, Russo PJournal of clinical oncology : official journal of the American Society of Clinical OncologyManagement of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017 Feb 20; 35(6):668-680.J Clin Oncol2017-01-17T00:00:002017Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline.Authorship 995111227234998Pearce SM, Golan S, Gorin MA, Luckenbaugh AN, Williams SB, Ward JF, Montgomery JS, Hafez KS, Weizer AZ, Pierorazio PM, Allaf ME, Eggener SEEuropean urologySafety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. Eur Urol. 2017 03; 71(3):476-482.Eur Urol2016-05-24T00:00:002016Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer.Authorship 99549628137740Wymer KM, Daneshmand S, Pierorazio PM, Pearce SM, Harris KT, Eggener SEAnnals of oncology : official journal of the European Society for Medical OncologyMildly elevated serum alpha-fetoprotein (AFP) among patients with testicular cancer may not be associated with residual cancer or need for treatment. Ann Oncol. 2017 04 01; 28(4):899-902.Ann Oncol2017-04-01T00:00:002017Mildly elevated serum alpha-fetoprotein (AFP) among patients with testicular cancer may not be associated with residual cancer or need for treatment.